Protocol I9X-MC-MTAE(e)
Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic 
Alzheimer's Disease
[STUDY_ID_REMOVED]
Approval Date: 01-Oct-2024
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
1 
  
Title Page   
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators.  It is the property of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_77109]3372689 , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries.  
 
Note to Regulatory Authorities:   This document may contain protected personal data and/or commercially confiden tial 
information exempt from public disclosure.  Eli Lilly and Company requests consultation regarding release/redaction prior to any 
public release.  In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may n ot be 
reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
Protocol Title:  Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early  
Symptomatic Alzheimer’s Disease  
Protocol Number:  I9X-MC-MTAE  
Amendment Number:  e 
Compound : LY3372689  
Study Phase:  2 
Short Title:  Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early 
Symptomatic Alzheimer’s Disease  
Sponsor Name:  [CONTACT_11028]:  Indianapolis, Indiana , [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Numbers : 
IND: [ADDRESS_943382]: [ADDRESS_943383] number:  2024 -512295 -36-00 
Approval Date:  Protocol  Amendment ( e) Electronically  Signed and  Approved  by [CONTACT_10937].   
Document  ID: VV-CLIN -[ADDRESS_943384] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943385] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
3 
 Protocol Amendment Summary of Changes Table   
DOCUMENT HISTORY  
Document  Date  
Amendment d  18-Apr-2024  
Amendment c 22-Mar-2024  
Amendment b 02-Sep-2021  
Amendment a  09-Jun-2021  
Original Protocol  06-Jan-2021  
Amendment [e] 
This amendment is considered to be substantial.  
The amendment is considered to be substantial because it is likely to have a significant impact on 
the safety or the rights of the study participants . 
Overall Rationale for the Amendment : 
The main rationale for this amendment is  the follow -up of safety findings and biomarker changes 
that e merged during the double -blind  treatment period . The key changes include re placing  the 
optional  open -label extension (OLE ) period  with post -treatment safety follow -up period and  
removing the flortaucipir F18 PET imaging and MRI substudy . 
Minor editorial and formatting changes are not included in this table.   
Section # and Name  [CONTACT_11029]  
1.1 Synopsis   Deleted objective and endpoint 
of the OLE period  
 Overall Design subsection: 
Deleted sentence regarding 
OLE consent and duration  
 Intervention Groups and 
Duration subsection:  
Revised study duration from 
“217” to “149” weeks  
Deleted OLE period and 
safety follow -up (V802)  
Added post -treatment safety  
follow -up period and 
corresponding duration  To align with the chan ges made to the 
study design (replacing the OLE period 
with post -treatment safety follow -up 
period)  
1.2. Schema  Deleted schema depi[INVESTIGATOR_695414]  
1.3.4. Study Period [ADDRESS_943386]-treatment Safety 
Follow -up Period   Revised occurrence of OLE 
period to Post -treatment 
Safety Follow -up Period  
 Deleted V31 through V802  
(except V32)  
Approved on [ADDRESS_943387] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
4 
 Section # and Name  [CONTACT_11029]  
 Retained V32 as V 803 
 Revised ECG comments to 
read as: “single ECG with 
central reads”  
 V802 (previously V30)  
changes: Added MRI imaging  
 V803 (previously V31)  
changes: Added CDR, 
ADAS -Cog 13, ADCS -ADL, 
MMSE  
 Laboratory Tests and Sample 
Collections row: Added 
comment for testosterone, 
LH, FSH and Inhibin B that it 
will be collected only in men  
 Exploratory Biomarker 
Samples row: Added 
comments “Includes P -Tau” 
 Deleted footnotes that are no 
longer applicable  and re -
arranged the sequence  
3. Objectives and 
Endpoints   Replaced the table for OLE 
period with objectives and 
endpoints for the post -
treatment safety follow -up 
period  
4.1. Overall Design   Revised study duration from 
“217” to “149” weeks  
 Deleted OLE period and safety 
follow -up (V802)  
 Added post -treatment safety 
follow -up period and 
corresponding duration  
 Deleted paragraph detailing 
specifics of the OLE period  
4.1.5. Post-treatment 
Safety Follow -up 
Period   Deleted paragraph on OLE 
period  (V30 -V37)  and follow -
up (V80 2) 
 Added activities during the 
post-treatment safety follow -
up period  
4.2. Scientific 
Rationale for Study 
Design  Deleted paragraph on ratio nale for 
the OLE study design  
Approved on [ADDRESS_943388] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
5 
 Section # and Name  [CONTACT_11029]  
4.3. Justification for 
Dose  Deleted paragraph for the OLE 
dose selection  
5.2. Exclusion Criteria  Deleted criterion 44, [ADDRESS_943389] -Treatment 
Safety Follow -up 
Period (newly added 
section)  Added exclusion criterion 47  
6. Study Intervention  Deleted treatment regimen table 
for OLE period  
6.3. Measures to 
Minimize Bias: 
Randomization and 
Blinding   Deleted sentence “The 
extension phase of this study 
is open -label”  
 Revised OLE period to Post -
treatment Safety Follow -up 
Period in the last paragraph  
6.5.1. Standard of 
Care for Alzheimer’s 
Disease  Revised occurrence of OLE 
period to Post -treatment Safety 
Follow -up Period in the last 
paragraph and replaced the visits 
from “V30 -V37” to “V 802 and 
V803” 
6.6. Dose 
Modification  Deleted last paragraph detailing 
dose modification during the OLE 
period  
6.7. Intervention after 
the End of the Study   Deleted statement that optional 
OLE will be offered to 
participants who complete the 
study through the double -
blind study periods  
 Added “study intervention will 
not be made available to 
participants after conclusion 
of the study”  
9.4.1. General 
Considerations   Revised occurrence of OLE 
period to Post -treatment  
Safety  Follow -up Period  
 Updated paragraph to capture 
the study will include 2 SAPs 
(previously several separate 
SAPs), and a supplemental 
SAP to detail additional 
exploratory analyses related 
to biomarkers  
Approved on [ADDRESS_943390] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
6 
 Section # and Name  [CONTACT_11029]  
10.10. Appendix 10: 
Flortaucipir F18 PET 
Imaging and MRI 
Substu dy Deleted substudy  
  
Approved on [ADDRESS_943391] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
7 
 Table of Contents   
1. Protocol Summary  ................................ ................................ ................................ ........ 10 
1.1. Synopsis  ................................ ................................ ................................ .......................... 10 
1.2. Schema  ................................ ................................ ................................ ............................ 14 
1.3. Schedule of  Activities (SoA)  ................................ ................................ .......................... [ADDRESS_943392]-treatment Safety Follow -up Period  ................................ ............... 27 
2. Introduction  ................................ ................................ ................................ ................... 29 
2.1. Study Rationale  ................................ ................................ ................................ ............... 29 
2.2. Background  ................................ ................................ ................................ ..................... 29 
2.2.1.  Nonclinical Studies  ................................ ................................ ................................ ......... 29 
2.2.2.  Clinical Studies  ................................ ................................ ................................ ............... 30 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 31 
2.3.1.  Benefit Assessment  ................................ ................................ ................................ ......... 32 
2.3.2. Overall Benefit/Risk Conclusion  ................................ ................................ .................... 33 
3. Objectives and Endpoints  ................................ ................................ ............................ 34 
4. Study Design  ................................ ................................ ................................ .................. 37 
4.1. Overall  Design  ................................ ................................ ................................ ................ 37 
4.1.1.  Lead -In and Screening Period (V601 and V1)  ................................ ............................... 37 
4.1.2.  Double -Blind Period 2a (V2 -21) ................................ ................................ .................... 38 
4.1.3.  Double -Blind Period 2b (V22 -29) ................................ ................................ .................. 38 
4.1.4.  Follow -up (V801)  ................................ ................................ ................................ ........... [ADDRESS_943393]-Treatment Safety Follow -up Period (V802 and V803)  ................................ .......... [ADDRESS_943394]-Treatment Safety Follow -up Period  ................................ ................................ .......45 
5.4. Lifestyle Considerations  ................................ ................................ ................................ .45 
5.5. Screen Failures  ................................ ................................ ................................ ................ 46 
6. Study  Intervention  ................................ ................................ ................................ ........ 47 
6.1. Study Intervention(s) Administered ................................ ................................ ................ 47 
6.2. Preparation/Handling/Storage/Accountability  ................................ ................................ 48 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ [ADDRESS_943395] of Care for Alzheimer’s Disease ................................ ................................ ......[ADDRESS_943396] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
8 
 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 52 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 52 
7.1.1.  Temporary Discontinuation  ................................ ................................ ............................ 53 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ [ADDRESS_943397] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
9 
 9.4. Statistical Analyses  ................................ ................................ ................................ ......... 71 
9.4.1.  General Considerations  ................................ ................................ ................................ ...71 
9.4.2.  Primary Endpoint(s)  ................................ ................................ ................................ ........ 72 
9.4.3.  Secondary Endpoint(s)  ................................ ................................ ................................ ....73 
9.4.4.  Tertiary/Exploratory Endpoint(s) ................................ ................................ .................... 74 
9.4.5.  Treatment Group Comparability  ................................ ................................ ..................... 74 
9.4.6.  Safety Analyses(s)  ................................ ................................ ................................ .......... 75 
9.4.7.  Other Analyses  ................................ ................................ ................................ ................ 75 
9.5. Interim Analyses  ................................ ................................ ................................ ............. 75 
9.6. Data Monitoring Committee  ................................ ................................ ........................... 76 
10. Supporting Documentation and Operational Considerations  ................................ ..77 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 77 
10.1.1.  Regulatory and  Ethical Considerations  ................................ ................................ ........... 77 
10.1.2.  Financial Disclosure ................................ ................................ ................................ ........ 77 
10.1.3.  Informed Consent Process  ................................ ................................ .............................. 78 
10.1.4.  Data Protection ................................ ................................ ................................ ................ 78 
10.1.5.  Committees Structure ................................ ................................ ................................ ......79 
10.1.6.  Dissemination of Clinical Study Data ................................ ................................ ............. 79 
10.1.7.  Data Quality Assurance  ................................ ................................ ................................ ..80 
10.1.8.  Source Documents  ................................ ................................ ................................ .......... 81 
10.1.9.  Study and Site Start and Closure  ................................ ................................ .................... 82 
10.1.10.  Publication Policy  ................................ ................................ ................................ ........... 82 
10.1.11.  Investigator Information  ................................ ................................ ................................ .82 
10.1.12.  Long -Term Sample Retention ................................ ................................ ......................... 82 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 84 
10.3.  Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  ................................ ......................... [ADDRESS_943398] Complaints  ................................ ................................ ................... 88 
10.3.4.  Recording and Follow -Up of AE and/or SAE and Product 
Complaints  ................................ ................................ ................................ ...................... 88 
10.3.5.  Reporting of SAEs  ................................ ................................ ................................ .......... 90 
10.3.6.  Regulatory Reporting Requirements  ................................ ................................ ............... 91 
10.4.  Appendix 4:  Liver Safety:  Suggested Actions and Follow -Up 
Assessments  ................................ ................................ ................................ .................... 92 
10.5.  Appendix 5:  Flortaucipir F18 Tau PET Imaging  ................................ ........................... 94 
10.6.  Appendix 6: Contraceptive Guidance and Collection of 
Pregnancy Information  ................................ ................................ ................................ ...95 
10.7.  Appendix 7: Genetics ................................ ................................ ................................ ......[ADDRESS_943399] During 
Exceptional Circumstances  ................................ ................................ ............................. 97 
10.9.  Appendix 9: Abbreviations  ................................ ................................ ........................... 101 
10.10.  Appendix 10: Protocol Amendment History  ................................ ................................ [ADDRESS_943400] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
10 
 1.  Protocol Summary   
1.1. Synopsis   
Protocol Title:  Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early 
Symptomatic Alzheimer’s Disease  
Short Title : Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early 
Symptomatic Alzheimer’s Disease  
Regulatory Agency Identifier Numbers : 
IND: [ADDRESS_943401]: [ADDRESS_943402] number:  2024 -512295 -36-00 
Rationale : 
LY3372689 is an orally available, potent inhibitor of O-linked N -acetyl glucosaminidase ( OGA ). 
This glycoside hydrolase is the enzyme that removes the single -sugar modification, O -linked  β-
N-acetyl glucosamine (O -GlcNAc), from intracellular proteins including the microtubule 
associated protein tau. This modification is regulated by [CONTACT_243341] 2  enzymes, O -GlcNAc 
transferase (OGT) and OGA.   
By [CONTACT_695433], LY3372689 is hypothesized to delay the progression of tau  aggregation -
related diseases by [CONTACT_695434], insoluble tau filaments 
within cells of the central nervous system ( CNS ), resulting in reduced propagation of tau 
pathology and pr eserved neuronal function.   
Objectives and Endpoint s: 
Primary Objective  Endpointsa 
To assess the effect of LY3372689 vs. placebo 
on clinical progression in participants with 
early symptomatic AD with demonstrated 
presence of moderateb levels  of tau pathology  iADRS  change from baseline through  end time point 
(76-124 weeks)  
Key Secondary Objective  Endpoints  
To assess the effect of LY3372689 vs. placebo 
on clinical progression in full study population 
(moderate + highc levels of  tau pathology ) with 
early symptomatic AD  iADRS  change from baseline through  end time point 
(76-124 weeks)  
Other Secondary Objectives  Endpoints  
To evaluate safety and tolerability of 
LY3372689  Standard safety assessments  
 Spontaneously reported AEs  
Approved on [ADDRESS_943403] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
11 
  Clinical laboratory tests  
 Vital sign and body weight measurements  
 12-lead ECGs  
 Physical and neurological examinat ions 
 C-SSRS, and  
 MRI (treatment -emergent radiological 
findings)  
To assess the effect of LY3372689 vs. placebo 
on clinical progression in full study population 
and moderate tau sub population with early 
symptomatic AD  Change in cognition and function from baseline 
through  end time point (76-124 weeks)  as measured 
by: 
 ADAS -Cog 13 
 ADCS -iADL  
 CDR -SB, and  
 MMSE  
To assess the effect of LY3372689 vs. placebo 
on brain region volumes  Change in  volumetric MRI measures from baseline 
through  end time point (76 - 124 weeks ) 
To assess the effect of LY3372689 vs. placebo 
on brain tau deposition  Change in brain  tau deposition  from baseline through 
end time point (76-100 weeks) as measured by  
[CONTACT_560452] F18 PET scan  
To assess the PK of LY3372689  Plasma concentrations of LY3372689  
Abbreviations: ADAS -Cog 13 = Alzheimer’s Disease Assessment Scale – Cognitive subscale; ADCS -iADL = 
Alzheimer’s Disease Cooperative Study – instrumental Activities o f Daily Living; AD = Alzheimer’s Disease; 
AE = Adverse Event; CDR -SB = Clinical Dementia Rating Scale - Sum of Boxes ; C-SSRS = Columbia Suicide -
Severity Rating Scale;  ECG = electrocardiograms; iADRS = integrated Alzheimer’s Disease Rating Scale; 
MMSE = Mini  Mental State Examination; MRI = Magnetic Resonance Imaging; PET = Positron emission 
tomography; PK = Pharmacokinetics.  
a Based on common close design , participants final endpoint time will be between 76 -124 weeks.  
b Moderate tau pathology is defined as those who meet tau PET inclusion criteria for evidence of tau pathology 
consistent with Alzheimer’s disease (Fleisher et al. 2020), but do not have wides pread and high levels of cortical 
tau pathology.  
c  High levels of cortical tau pathology by [CONTACT_560452] F18 PET is defined by [CONTACT_695435] u ptake value ratios in a population of amyloid positive Alzheimer’s participants and cognitively 
normal older controls (Pontecorvo et al. 2019).
Approved on [ADDRESS_943404] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
12 
 Overall Design : 
Study I9X-MC-MTAE  (MTAE ) is a multicenter, randomized, double -blind , placebo -controlled, 
Phase 2 study of LY3372689 in participants with early symptomatic Alzheimer’s disease  (AD). 
This study will utilize a [ADDRESS_943405] enrolled participant  that ha s not discontinued from treatment has 
achieved 76 weeks of assigned treatment . The maximum duration of treatment is 124 weeks.   
Study Population:  
Eligible participants will have a gradual and progressive change in memory function with Mini 
Mental State Examination (MMSE ) 22-30, Clinical Dementia Rating Scale (CDR ) global score 
of 0.5 to 1.0, with a memory box score ≥0.5. Particip ants who meet pla sma P -tau and flortaucipir 
F18 PET scan criteria  will be eligible . Prior treatments with disease -modifying therapy  or any 
commercially approved prescription medication for the treatment of AD , which meet study 
criteria are allowed.  Partici pants who fail to complete the required psychometric tests , those with 
medical conditions , such as significant neurological disease affecting the CNS,  cardiovascular, 
hepatic, renal, gastroenterological, respi[INVESTIGATOR_696], endocrinologic, neurologic, psychiatric, 
immunologic, hematologic disease , or cancer , may be excluded  from  participation in the study.  
Number of Participant s: 
Approximately 110 participants will be randomly assigned per arm for a total of 330 randomized 
participants for study interve ntion.  
Intervention Groups and Duration:  
Participants who meet entry criteria will be randomized in a 1:1:1 (1 LY:  1 LY: 1 PBO) 
randomization to the following treatment groups:   
 LY3372689: low dose  daily  
 LY3372689: high dose  daily , and  
 Placebo . 
The maximu m total duration of study participation for each participant, including screening and 
the post -treatment follow -up periods, is up to approximately 149 weeks:   
 Lead -In: complete any time prior to complete screening visit  
 Complete Screening: -63 days to -1 day prior to randomization  
 Double -Blind: 76 weeks or up to 124 weeks  
 Safety Follow -up (V801) : approximately 4 weeks after completion of double -blind study 
period  2b, and  
 Post-treatment Safety Follow -up period : approximately [ADDRESS_943406] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
13 
 Ethical Considerations of Benefit/Risk:  
The available nonclinical and clinical data support the oral administration of LY3372689 t o the 
intended study population according to the clinical investigation plan and also provide a 
sufficient margin of safety for the study design and doses. There are currently no disease -
modifying anti -tau treatments for AD. The potential benefits of LY3372689  showing disease -
modifying properties in participants with AD are considered to outweigh the potential risks.  
Data Monitoring Committee: Yes
Approved on [ADDRESS_943407] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
14 
 1.2. Schema   
 
a Study I9X-MC-MTAE  (MTAE ) has a common close design in which all enrolled participants continue to study Period 2b until the last enrolled participant  
that has not discontinued from  treatment reach es [ADDRESS_943408] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
15 
 1.3.   Schedule of Activities (SoA)   
1.3.1.  Study Period 1 -Screening   
Study Period 1 - Screeninga                                                                                                                                                                                                                                                            
 LEAD -IN 
SCREENING  COMPLETE 
SCREENING  Comments  
Visit No.:  601  1  
Days Relative to 
Randomization  Can be done 
any time prior 
to V1 -63 to -1 
(≤63 before V2)   
Tolerance Interval for 
Visit (Days)  Can be done 
any time  ≤63 before V2   
Entry and Administrative  
Abbreviated or full 
informed consent 
(participant and study 
partner)  X  The abbreviated informed consent grants consent only for procedures and assessments 
marked under V601.  
Study partner(s) is(are) not required to complete the abbreviated informed consent 
form.  
Full informed consent 
(participant  and study 
partner)   X Do not collect if full informed consent was collected at V601.  
Inclusion and exclusion 
criteria, review , and confirm   X Confirm that the participant has met all V1 eligibility criteria before proceeding to V2 
procedures.  
Demographics  X X Do not collect demographics at V1 if collected at V601 . 
Preexisting conditions and 
medical history, including 
relevant surgical history   X  
Prespecified medical history 
(indication and history of 
interest)   X  
Substance use (alcohol, 
caffeine, and tobacco use)   X  
Concomitant medications   X  
AEs  X  
 
Approved on [ADDRESS_943409] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
16 
 Study Period 1 - Screeninga                                                                                                                                                                                                                                                            
 LEAD -IN 
SCREENING  COMPLETE 
SCREENING  Comments  
Visit No.:  601  1  
Days Relative to 
Randomization  Can be done 
any time prior 
to V1 -63 to -1 
(≤63 before V2)   
Tolerance Interval for 
Visit (Days)  Can be done 
any time  ≤63 before V2   
Physical Evaluation  
Height   X  
Weight   X  
Vital signs   X BP, pulse, and temperature (after 5 min in sitting position).  
Physical examination   X  
12-lead ECG (central)   X Triplicate ECG  
PET Scans and MRI  
Flortaucipir F18  PET 
scanb,c,d  X A historical flortaucipir F18  PET scan may be submitted to be considered for eligibility if 
performed within 6 months of randomization. The acceptance of a historical scan is at the 
discretion of the sponsor.  
MRIb,d   X  
Clinician -Administered Assessments (Electronic)e 
CDR   X The CDR must always be administered to the study partner first and then to the 
participant.  
MMSE  X X Do not perform MMSE at V1 if collected at V601, unless >3 months since V601.  
Laboratory Tests and Sample Collections  
Hematology   X  
Clinical chemistry   X  
Hepatitis B virus (HBV) 
Screening  tests   X Perform at screening in participants with a past history (suspected or confirmed) of 
Hepatitis B.  
Hepatitis C virus (HCV) 
Screening tests   X Perform at screening in participants with a past history (suspected or confirmed) of 
Hepatitis C  (resolved >6 months prior to enrollment).  
Approved on [ADDRESS_943410] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
17 
 Study Period 1 - Screeninga                                                                                                                                                                                                                                                            
 LEAD -IN 
SCREENING  COMPLETE 
SCREENING  Comments  
Visit No.:  601  1  
Days Relative to 
Randomization  Can be done 
any time prior 
to V1 -63 to -1 
(≤63 before V2)   
Tolerance Interval for 
Visit (Days)  Can be done 
any time  ≤[ADDRESS_943411] 
exploratory biomarker samples  at V1 if collected at V601 . 
Abbreviations: AD = Alzheimer’s Disease; AE = adverse event; BP = blood pressure; CDR = Clinical Dementia Rating Scale; C -SSRS = Columbia Suicide 
Severity Rating Scale; DSST = Digit Symbol Substitution Test; ECG = electrocardiogram; MMSE = Mini Mental Stat e Examination; MRI = magnetic 
resonance imaging; PET = positron emission tomography; V = Visit . 
a Visit 1 procedures may be conducted over more than 1 day as long as all activities are completed within the allowable visit t olerance.   
b The participant should meet all other eligibility criteria before the screening flortaucipir F18 PET scan and MRI .   
c If results are received after the 63 -day screening period, the participant remains eligible contingent on meeting the other eligibility criteria.  May require review 
and/or retest of screening safety labs if >63 days between V1 and V2.  
d If plasma P -tau testing is not available to the site for eligibility determination  at the time of screening, the sample should still be collected and submitted. In 
such cases , the participant may proceed to screening flortaucipir F18 PET scan and MRI if all other screening  requirements are met, with no requirement to 
document plasma P -tau eligibility results. Sites will be notified if this situation applies. This will not be considered a protocol deviation.  
e Administer prior to medical procedures that could be stressful to  the participant (blood draws, etc.). These tests include the audio voice recording of the rater’s 
questions and the participant and study partner responses to assessment questions.  
Approved on [ADDRESS_943412] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
18 
 1.3.2.  Study Period 2a -Treatment Period   
 Study Period 2a  - Treatment period a  
Visit No.:  
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 ET 
(Period 
2a) Comments  
Week s Relative to 
Randomization  0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76   
Rem ote Visit 
Option             X    X   X   Remote home visits are 
an option to on-site 
visit . 
Televisits            X  X  X   X    Visits are to be 
performed by [CONTACT_648].  
Tolerance  
interval for visit  
(Days)  0 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7   
Randomization  X                      
Inclusion and 
exclusion criteria  X                      
Concomitant 
medications  X X X X X X X X X X X X X X X X X X X X X  
AEs X X X X X X X X X X X X X X X X X X X X X  
Physical Evaluation  
Weight  X   X   X   X    X   X   X X  
Vital signs  X X X X X X X X X X  X  X  X X  X X X BP, pulse, and 
temperature ( after  5 
min in sitting position).  
In addition, orthostatic 
BP and pulse will be 
measured at V2, V5, V8, 
V11, V15, V18, V21, ET, 
and unscheduled visits.   
Physical/ neuro 
examination  X X  X   X   X    X   X   X X  
Approved on [ADDRESS_943413] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
19 
  Study Period 2a  - Treatment period a  
Visit No.:  
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 ET 
(Period 
2a) Comments  
Week s Relative to 
Randomization  0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76   
Rem ote Visit 
Option             X    X   X   Remote home visits are 
an option to on-site 
visit . 
Televisits            X  X  X   X    Visits are to be 
performed by [CONTACT_648].  
Tolerance  
interval for visit  
(Days)  0 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7   
Symptom -directed 
physical 
examination    X  X X  X X   X    X   X    
12-lead ECG 
(central)  X X X X X X X   X    X   X   X X Single ECG  
PET Sc ans and MRI  
Flortaucipir F18  
PET scan                      X X b No more than one PET 
scan should be obtained 
in Period 2a . 
MRI                X      X Xc MRI not performed  if 
<[ADDRESS_943414] 
MRI .  
Clinician -Administered Assessments (Electronic) d 
ADAS -Cog [ADDRESS_943415] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
20 
  Study Period 2a  - Treatment period a  
Visit No.:  
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 ET 
(Period 
2a) Comments  
Week s Relative to 
Randomization  0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76   
Rem ote Visit 
Option             X    X   X   Remote home visits are 
an option to on-site 
visit . 
Televisits            X  X  X   X    Visits are to be 
performed by [CONTACT_648].  
Tolerance  
interval for visit  
(Days)  0 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±[ADDRESS_943416]  X X X X X X X   X    X   X   X Xe  
Digital clock  X X X X X X X   X    X   X   X Xe  
Clinician -Administered Assessments (Paper)  
C-SSRS  baseline  X                      
C-SSRS since last 
visit  X X X X X X X X X X X X X X X X X X X X  
Laboratory Tests and Sample Collectionsg 
Hematology  X X X X   X   X    X   X   X X  
Clinical chemistry  X X X X   X   X    X   X   X X  
Urinalysis  X      X       X      X X  
Estrogen h X   X   X              Xi  
Testosteroneh X   X   X             X Xi 
 LHh X   X   X             X Xi 
FSHh X   X   X             X Xi 
Inhibin Bh X   X   X             X Xi 
ApoE j X                      
PK sample  X k Xl X    X   X    X   X    Xm  
Approved on [ADDRESS_943417] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
21 
  Study Period 2a  - Treatment period a  
Visit No.:  
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 ET 
(Period 
2a) Comments  
Week s Relative to 
Randomization  0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76   
Rem ote Visit 
Option             X    X   X   Remote home visits are 
an option to on-site 
visit . 
Televisits            X  X  X   X    Visits are to be 
performed by [CONTACT_648].  
Tolerance  
interval for visit  
(Days)  0 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±[ADDRESS_943418] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
22 
 Abbreviations:  ADAS -Cog 13 = Alzheimer’s Disease Assessment Scale – Cognitive subscale; ADCS -ADL = Alzheimer’s Disease Cooperative Study – Activities 
of Daily Living; AE = Adverse Event; ApoE = Apolipoprotein E; BP = blood pressure; ECG = electrocardiogram; CDR = Clinical Dementia Rating Scale; C -
SSRS = Columbia Suicide Severity Rating Scale; DSST = Digit Symbol Substitution Test; ET = Early Termination; FSH = Follicle Stimulating Hormone; IP 
= Investigational Product; IWRS  = interactive web -response system; LH = Luteinizing Hormone ; MMSE = Mini Mental State Examination; MRI = magnetic 
resonance imaging; PET = positron emission tomography; PK = pharmacokinetics; V = Visit  
a Procedures for some visits may take more than [ADDRESS_943419], and Digital Clock  prior to medical procedures that co uld be stressful to the participant (blood 
draws, etc.). These tests include the audio voice recording of the rater’s questions and the participant and study partner re sponses to assessment questions.  
e For participants who permanently discontinued from IP  but remain in the study, cognitive assessments should be performed only if they coincide with a 
protocol -defined study window where cognitive testing would have otherwise occurred during Period 2a as defined by [CONTACT_695436].   
For participants who permanently discontinue from IP and the study, cognitive assessments should be performed only if >[ADDRESS_943420] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
23 
 1.3.3.  Study Period 2b -Treatment Period   
 
Study Period 2b  - Common Close (or Treatment Beyond Week 76)  a Study Period 
3-Post -
treatment 
safety follow -
up period   
Visit No.:  22 23 24 25 26 27 28 29 ET (Period 2b)  
b V801  
4 weeks±10 
days after 
participant’s 
last Study 
Period 2 visit  Comments  
Weeks relative to 
Randomization  82 88 94 100  106  112  118  124    
Televisit  X  X  X  X   Visits to be performed by 
[CONTACT_648].  
Tolerance interval for visit 
(days)  ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±7   
Concomitant medications  X X X X X X X X X X  
AEs X X X X X X X X X X  
Physical Evaluation  
Weight   X  X  X  X X X  
Vital signs  
 X  X  X  X X X BP, pulse, and temperature 
(after 5 min in sitting position). 
In addition, orthostatic BP and 
pulse will be measured at V23, 
V25, V27, V29, and ET.  
Physical/neuro examination   X  X  X  X X X  
12-lead ECG (central)   X  X  X  X X X Single ECG.  
PET Scans and MRI  
Flortaucipir F18 PET scan     X     Xc  No more than one PET scan 
should be obtained in Period 2b.  
MRI     X    X Xd  MRI not performed if <[ADDRESS_943421] MRI assessment.  
Clinician -Administered Assessments (Electronic)  e 
ADAS -Cog [ADDRESS_943422] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
24 
  
Study Period 2b  - Common Close (or Treatment Beyond Week 76)  a Study Period 
3-Post -
treatment 
safety follow -
up period   
Visit No.:  22 23 24 25 26 27 28 29 ET (Period 2b)  
b V801  
4 weeks±10 
days after 
participant’s 
last Study 
Period 2 visit  Comments  
Weeks relative to 
Randomization  82 88 94 100  106  112  118  124    
Televisit  X  X  X  X   Visits to be performed by 
[CONTACT_648].  
Tolerance interval for visit 
(days)  ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±[ADDRESS_943423]   X  X  X  X Xf   
Digital Clock   X  X  X  X Xf   
Clinician -Administered Assessments (Paper)  
C-SSRS Since Last Visit  X X X X X X X X X X  
Laboratory Tests and Sample Collectionsg 
Hematology   X  X  X  X X X  
Clinical chemistry   X  X  X  X X X  
Urinalysis          X X  
PK sample           Xh   
Testosteronei  X  X  X  X X X Collected only in men  
LHi  X  X  X  X X X 
FSHi  X  X  X  X X X 
Inhibin Bi  X  X  X  X X X 
Exploratory Endpoint and Stored Samples  
Exploratory Biomarker 
Samplesj  X  X  X  X X   
Approved on [ADDRESS_943424] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
25 
  
Study Period 2b  - Common Close (or Treatment Beyond Week 76)  a Study Period 
3-Post -
treatment 
safety follow -
up period   
Visit No.:  22 23 24 25 26 27 28 29 ET (Period 2b)  
b V801  
4 weeks±10 
days after 
participant’s 
last Study 
Period 2 visit  Comments  
Weeks relative to 
Randomization  82 88 94 100  106  112  118  124    
Televisit  X  X  X  X   Visits to be performed by 
[CONTACT_648].  
Tolerance interval for visit 
(days)  ±7 ±7 ±7 ±7 ±7 ±7 ±7 ±[ADDRESS_943425] IWRS  X X X X X X X X X X  
Dispense study drug   X  X  X     Drug to be dispensed at prior 
in-person visit for televisits  
Participant returns study 
drug   X  X  X  X X   
Assess study drug 
compliance  X X X X X X X X X   
Abbreviations:  ADAS -Cog 13 = Alzheimer’s Disease Assessment Scale – Cognitive subscale; ADCS -ADL = Alzheimer’s Disease Cooperative Study – Activities 
of Daily Living; AE = Adverse Event; BP = blood pressure; CDR = Clinical Dementia Rating Scale; C -SSRS = Columbia Suicide Severity R ating Scale; 
DSST = Digit Symbol Substitution Test; ECG = electrocardiogram; ET = Early Termination; IP = Investigational Product; MMSE = Mini Mental State 
Examination; MRI = magnetic resonance imaging; PET = positron emission tomography; PK = pharmacokine tics; V = Vi sit. 
a All participants are to complete Period 2a and continue to period 2b/[ADDRESS_943426] visit in treatment period , see the activities listed for ET in this table.  
b For participants in Period 2b  at the time of the common close ( that is,  when the last participant complete s 76 weeks of treatment ), the ET visit activities are to 
be conducted as the next and final Period 2b visit , the End -of-Study ET Visit . 
c ET PET scan only to be performed if ET occurs at Week 100 ± [ADDRESS_943427] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943428], and Digital Clock  prior to medical procedures that could be stressful to the participant (blood 
draws, etc.). These tests include the audio voice recording of the rater’s questions and the participan t and study partner responses to assessment questions.  
f For participants who permanently discontinue from IP but remain in the study, cognitive assessments should be performed only if they coincide with a protocol -
defined study window where cognitive test ing would have otherwise occurred during Period 2b as defined by [CONTACT_695436].   
For participants who permanently discontinue from IP and the study, cognitive assessments should be performed only if >[ADDRESS_943429] otherwise occurred as defined by [CONTACT_695437] >[ADDRESS_943430] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943431]-treatment Safety Follow -up Period   
Note:  All random ly assigned  participants are eligible for participation.  
Visit No.:  802  803  Comments  
Weeks  0 12  
Tolerance interval for visit (days)  ±7 ±7  
Informed consent (participant and study partner)  X  Reconsent must be completed prior to initiating Visit 
802 procedures.  
Concomitant medications  X X  
AEs X X  
Physical Evaluation  
Weight  X X  
Vital signs  X X  
Physical/neuro examination  X   
Symptom -directed physical examination   X  
12-lead ECG (central)  X X Single ECG with central reads.  
Imaging  
MRI  X   
Clinician -Administered Assessments (Electronic)a 
CDR  X X The CDR must always be administered to the study 
partner first and then to the participant.  
ADAS -Cog 13 X X  
ADCS -ADL  X X  
MMSE  X X  
Clinician -Administered Assessments (Paper)  
C-SSRS Since Last Visit  X X  
Laboratory Tests and Sample Collectionsb 
Hematology  X X  
Clinical chemistry  X X  
Testosteronec X X Collected only in men . 
LHc X X 
FSHc X X 
Inhibin Bc X X 
Approved on [ADDRESS_943432] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
28 
 Visit No.:  802  803  Comments  
Weeks  0 12  
Tolerance interval for visit (days)  ±7 ±7  
Exploratory Endpoint and Stored Samples  
Exploratory Biomarker Samplesd X X Includes P -Tau.  
Abbreviations:  ADAS -Cog 13 = Alzheimer’s Disease Assessment Scale – Cognitive subscale; ADCS -ADL = Alzheimer’s Disease Cooperative Study – Activities 
of Daily Living; AE = adverse event; CDR = Clinical Dementia Rating Scale ; ECG = electrocardiogram;  ET = early termination;  C-SSRS =  Columbia 
Suicide Severity Rating Scale; ET = Early Termination; FSH = follicle stimulating hormone; IWRS  = interactive web -response system; LH = luteinizing 
hormone; MMSE = mini mental state examination; OLE = open -label extension; PK = pharmacokinetics; V = Visit . 
a Administer the ADAS -Cog13, ADCS -ADL, CDR, and MMSE prior to medical procedures that could be stressful to the participant ( for example, blood draws). 
These tests include the audio voice recording of the rater’s questions and the participant an d study partner responses to assessment questions.  
b  Unscheduled lab oratory  tests may be performed at the discretion of the investigator. Collect labs prior to administration of IP, unless otherwise no ted. Record 
the date and times of sample collection on the Lab Requisition Form.  
c   Hormone panel to be collected in the morning.  
d Collect unless not allowed or unfeasible due to local regulations.  
 
 
Approved on [ADDRESS_943433] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
29 
 2. Introduction   
2.1. Study Rationale   
AD is an age -related neurodegenerative disorder characterized by a progressive decline in 
cognitive function and ability to perform activities of daily living that ultimately le ads to death 
due to complications of the disease. Pathologic hallmarks of AD identified at autopsy include the 
presence of neuritic amyloid -β plaques, tau neurofibrillary tangles (Hyman et al. 2012), and 
neuronal loss , particularly pr onounced  in brain regi ons important for cognition, such as the 
hippocampus and temporal cortex (Selkoe 1991).  Extent and pattern of tau pathology closely 
tracks with cognitive symptoms in AD ( Brier  et al.  2016 ; Pontecorvo  et al. 2019 ). The current 
Study MTAE aims to demonstrate  that LY3372689 slows cognitive and functional decline , and 
to assess safety of chronic administration,  in early symptomatic AD participant s demonstrating 
evidence of tauopathy. For the purposes of this study , early symptomatic AD is defined as those 
with mild cognitive impairment due to AD or mild Alzheimer’s dementia , consistent with stages 
2 through 4 of the FDA draft guidance entitled “ Early Alzheimer’s Disease: Developi[INVESTIGATOR_115889] . Guidance for Industry ” (February 2018; 
https://www.fda.gov/media/110903/download ) and the NIA-AA Research Framework: Toward a 
biological definition of Alzheimer’s disease  (Jack et al . 2018).  
2.2. Background   
OGA is a  glycoside hydrolase enzyme that removes the single -sugar modification O-GlcNAc  
from intracellular proteins , such as  microtubule -associated protein tau. OGA inhibitors increase 
tau O -GlcNAc levels by [CONTACT_695438] -sugar from unbound tau protein . 
This inhibition has  been shown to reduce the accumulation of hyperphosphorylated, insoluble 
tau, including neurofibrillary tangles , in animal models of tauopathy (Yuzwa et al. 2014; Graham 
et al. 2014; Hastings et al.  2017).   
LY3372689 is an orally available , potent inhibitor of OGA  and is  hypothesized to delay the 
progression of tau -related diseases by [CONTACT_695434], 
insoluble tau filaments within cells of the CNS , resulting in reduce d propagation of tau 
pathology and preserved neuronal function.  Reduction of tau propagation is hypothesized to slow 
clinical progression of people diagnosed with early symptomatic AD.  
2.2.1.  Nonclinical Studies   
Nonclinical studies demonstrate that LY3372689 engages the OGA en zyme target in vivo, 
inhibits OGA enzyme activity, and increases the levels of protein O -GlcNAc and tau O -GlcNAc 
levels in the brain of mice and rats after single and multiple doses. Treatment with another 
proprietary aminothiazole compound reduced patholo gic tau in the forebrain of the P301S tau 
transgenic mouse model following chronic (3 months) dosing.  
In vitro metabolism studies suggest that  
 Solubili ty and permeability data for 
LY3372689  are consistent with Biopharmaceutics Classification System Class [ADDRESS_943434] 2024 GMT
CCI
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
30 
 The toxicity of LY3372689 has been characterized in GLP nonclinical safety studies in Sprague -
Dawley rats and beagle dogs, including 9-month (dogs), 6 -month (rats), 28-day, and 2-day 
repeat -dose general toxicology studies, as well as genetic toxicology and safety pharmacology 
studies. The 9 -month and 6 -month repeat -dose toxicity studies included 13 -week reversibility 
periods. The 28-day repeat -dose toxicity studies included an 8 -week reversibility period in dogs 
and a 13 -week reversibility period in rats.  The 2 -day repeat -dose toxicity studies included a  14-
day reversibility period in both species . Developmental and reproductive  toxicology (DART) 
studies were performed in rats and rabbits.  
2.2.2.  Clinical Studies   
Overa ll LY3372689 has been evaluated in [ADDRESS_943435] 1 dose of LY3372689. In these 4 studies, no deaths or SAEs were 
reported. One discontinuation due to an AE was reported, influenza type  A in Study MTAC, and 
was not considered related to the study drug by [CONTACT_093].  
The SAD Study MTAA  was a Phase 1, placebo -controlled, randomized study in 23  healthy male 
and female participant s (15 males, 8 females; aged 22 to 63 years). Participa nts received 
LY3372689 (0.15 to 16  mg) and placebo in a crossover manner, over 3 study periods. Safety and 
PK data were collected for 7 days in each period.  LY3372689 exposure based on AUC0 -∞ and 
Approved on [ADDRESS_943436] 2024 GMT
CCI
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
31 
 Cmax increased in a generally dose -proportional manner from 0.6 to 16  mg. Safety data indicated 
that LY3372689 was well tolerated when administered as a single dose up to 16  mg.  
Study MTAB was a single -dose PET  study utilizing [ 18F]LY3316612  PET tracer to assess 
enzyme occupancy ( EO), and to establish the rel ationship between plasma LY3372689 
concentration and EO, after single oral doses of LY3372689 . Sixteen h ealthy males  were dosed 
0.25, 1, or [ADDRESS_943437] -dose at 1  mg only. In general, a 
dose- and concentration -dependent change in EO was observed. At 1 and 5  mg, near maximum 
EO (97% to 98%) was observed at [ADDRESS_943438] -dose. The EO at 5  mg declined slightly from 98% at 
2 h to 93% at [ADDRESS_943439] -dose. At 1  mg, the EO declined from 97% at 2 h, to 81% at 24 h, to 30% 
at [ADDRESS_943440] -dose. The EO at 0.25  mg was 26% at 2 h and 46% at 24  h. The PK profile of 
LY3372689 in this study was similar to what was observed in the prior single -dose SAD Study.  
Safety data indicated that LY3372689 was well tolerated up to 5 mg.  
Study MTAC was a Multiple Ascending Dose ( MAD ), placebo -controlled, randomized study in 
women of non -childbearing potential , vasectomized males , and [ADDRESS_943441] on the extent of exposure but a 43% decrease in C max with a delay in t max by 
5 h, compared to the fasted state.  In terms of safety , there was no dose dependency in incidence 
or severity for treatment -emergent AEs. There were no clinically significant changes in ECGs, 
including no evidence of QTc, nor PR interval prolongation. There were also no clinically 
significant changes in vital signs, neurological examinations, or safety laboratory tests , including 
male hormon es. 
Study MTAD was an open -label , nonrandomized, multiple -dose PET study, utilizing 
[18F]LY3316612 to assess OGA brain EO resulting from oral doses of LY3372689 administered 
QD for [ADDRESS_943442] administration (on Day 1) and last administration (on Day  14) 
of 1 mg LY3372689 given QD for 14 days. Initial results show no change in enzyme occupancy 
from Day 1 to Day 15 of the study . These data provide confidence  that brain OGA EO can be 
sustained with multiple dosing.  Overall, no dose -dependent relationship in incidence or severity 
of treatment -related AEs  was observed , and blood markers of inflammation or muscle injury 
were within normal limits. There were no clinically significant changes in vital signs, ECGs, 
neurological examinations, or safety laboratories, including male hormone  panel  and creatinine 
kinase.  
2.3. Benefit /Risk Assessment   
More detailed information about the known and expected benefits and risks and reasonably 
expected  AEs of LY3372689 may be found in the IB. 
Potential Risks of Cli nical Significance  
Approved on [ADDRESS_943443] 2024 GMT
CCI
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
32 
 Mitigation Strategy  
Summary/Rationale for Risk   
In summary , the available nonclinical and clinical safety data support administration of 
LY33726 [ADDRESS_943444] 2024 GMT
CCI
CCI
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
33 
 2.3.2.  Overall Benefit /Risk Conclusion   
In conclusion, the available nonclinical and clinical data support the oral administration of 
LY3372689 t o the intended study population according to the clinical investigation plan and also 
provide a sufficient margi n of safety for the study  design and doses. There are currently no 
disease -modifying anti -tau treatments for AD. The potential benefits of LY3372689  showing 
disease -modifying properties in participant s with AD are considered to outweigh the potential 
risks.  
 
Approved on [ADDRESS_943445] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943446] of LY3372689 vs. placebo on 
clinical progression in participants with early 
symptomatic AD with demonstrated presence of 
moderateb levels of  tau pathology  iADRS  change from baseline through end time 
point (76 -124 weeks)  
Key Secondary Objective  Endpoints  
To assess the effect of LY3372689 vs. placebo on 
clinical progression in full study population 
(moderate + highc levels of  tau pathology ) with 
early symptomatic AD  iADRS  change from baseline through end time 
point (76 -124 wee ks) 
Other Secondary Objectives  Endpoints  
To evaluate safety and tolerability of LY3372689  Standard safety assessments  
 Spontaneously reported AEs  
 Clinical laboratory tests  
 Vital sign and body weight measurements  
 12-lead ECGs  
 Physical and neurological examinations  
 C-SSRS, and  
 MRI (treatment -emergent radiological 
findings)  
To assess the effect of LY3372689 vs. placebo on 
clinical progression in full study population and 
moderate tau sub population with early 
symptomatic AD  Change in cogniti on and function from baseline 
through end time point (76-124 weeks)  as 
measured by:  
 ADAS -Cog 13 
 ADCS -iADL  
 CDR -SB, and  
 MMSE  
To assess the effect of LY3372689 vs. placebo on 
brain region volumes  Change in  volumetric MRI measures from 
baseline through end time point (76 - 124 weeks ) 
To assess the effect of LY3372689 vs. placebo on 
brain tau deposition  Change in brain tau deposition  from baseline 
through end time point (76-100 weeks) as 
measured by  [CONTACT_560452] F18 PET scan  
To assess the PK of LY3372689  Plasma concentrations of LY3372689  
Approved on [ADDRESS_943447] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943448] of LY3372689 vs placebo on 
blood -based biomarkers  Change from baseline through end time point (76 -
124 weeks) on blood -based biomarkers of AD 
pathology and neurodegeneration  
To assess the effect of LY3372689 vs placebo on 
additional assessments of cognition  Change from baseline through end time point (76 -
124 weeks) as measured by:  
 Digital Clock Drawing Test, and  
 DSST  
To explore the relationship between tau burden 
and clinical outcomes  Tau burden  
 Blood -based biomark ers, and  
 Flortaucipir F18 PET 
Clinical outcomes  
 ADAS -Cog 13 
 ADCS -iADL  
 CDR -SB 
 iADRS, and  
 MMSE  
To explore the relationship between blood -based 
biomarkers and imaging  Blood -based biomarkers  of AD pathology and 
neurodegeneration  
Imaging  
 Flortaucipir F18 PET, and  
 MRI  
To assess the efficacy of LY3372689  to prolong 
time to clinical progression  CDR global score  
Abbreviations: ADAS -Cog 13 = Alzheimer’s Disease Assessment Scale – Cognitive subscale; ADCS -iADL = 
Alzheimer’s Disease Cooperative Study – instrumental Activities of Daily Living; AD = Alzheimer’s Disease; AE = 
Adverse Event; CDR -SB = Clinical Dementia Rating Scale -Sum of Boxes ; C-SSRS = Columbia Suicide -Severity 
Rating Scale;  ECG = electrocardiograms; iADRS = integrated Alzheimer’s Disease Rating Scale; MMSE = Mini 
Mental State Examination; MRI = Magnetic Resonance Imaging; PET = Positron emission tomography; PK = 
Pharmacokinetics .  
a Based on common close design , participants final endpoint time will be between 76 -124 weeks.  
b Moderate tau pathology is defined as those who meet tau PET inclusion criteria for evidence of tau pathology 
consistent with Alzheimer’s disease (Fleisher e t al. 2020), but do not have widespread and high levels of cortical 
tau pathology.  
c High levels of cortical tau pathology by [CONTACT_560452] F18 PET is defined by [CONTACT_695439] a population of amyloid p ositive Alzheimer’s participants and cognitively 
normal older controls (Pontecorvo et al. 2019).  
Approved on [ADDRESS_943449] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943450]-Treatment Safety  Follow -up Period  
Objective s Endpoints  
To assess clinical effects after  previous  treatment 
with LY3372689 on clinical progression in 
participants  with early symptomatic AD who 
participated in  the double -blind treatment periods  Change in cognitive and functional assessments :  
 iADRS  
 ADAS -Cog13  
 ADCS -iADL  
 CDR -SB, and  
 MMSE  
To assess  safety effects after previous treatment 
with LY3372689  Standard safety assessments  
 spontaneously reported AEs  
 MRI (treatment -emergent radiological 
findings)  
 clinical laboratory tests  
 vital sign and body weight measurements  
 12-lead ECGs  
 physical and neurological examinations , 
and 
 C-SSRS  
To assess effect after previous treatment with 
LY3372689 on brain region volumes  Volumetric MRI  measures  
To assess effect after previous treatment with 
LY3372689 on blood -based biomarkers  Change from baseline through end time point on 
blood -based biomarkers of AD pathology and 
neurodegeneration  
Abbreviations: ADAS -Cog 13 = Alzheimer’s Disease Assessment Scale – Cognitive subscale; 
ADCS - iADL  = Alzheimer’s Disease Cooperative Study – instrumental Activities of Daily Living; AD = 
Alzheimer’s disease; AE = adverse  event; CDR -SB = Clinical Dementia Rating Scale -Sum of Boxes; C-SSRS = 
Columbia Suicide -Severity Rating Scale ; ECG = electrocardiogram;  iADRS = integrated Alzheimer’s Disease 
Rating Scale;  MMSE = mini mental state examination ; MRI = Magnetic Resonance Imaging . 
 
Approved on [ADDRESS_943451] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
37 
 4. Study Design   
4.1. Overall  Design   
Study MTAE is a multicenter, randomized, double -blind , placebo -controlled, Phase 2 study of 
LY3372689 in participants with early symptomatic AD. Participants who meet entry crit eria will 
be randomized in a 1:1:1 (1 LY:  1 LY: 1 PBO) randomization of the following treatment groups:   
 LY3372689: low dose  once daily  
 LY3372689: high dose  once daily , and  
 Placebo . 
The maximum total duration of study participation for each participant, i ncluding screening and 
the post -treatment follow -up periods, is up to approximately 149 weeks:   
 Lead -In: complete any time prior to complete screening visit 
 Complete Screening:  -63 days to -1 day prior to randomization    
 Double -Blind: 76 weeks or up to 124 weeks  
 Safety Follow -up (V801): approximately 4 weeks after completion of double -blind study 
period 2b , and  
 Post-treatment Safety Follow -up Period: approximately [ADDRESS_943452] enrolled participant that has not discontinued from tre atment has 
achieved 76 weeks of assigned treatment . The maximum duration of treatment is 124 weeks.   
4.1.1.  Lead -In and Screening Period (V601 and V1)  
At or before Visit 1, the study will be explained to the participant  (and his or her legal 
representative,  if applicable) and study partner. Informed consent must be obtained before any 
study procedures  are conducted. The lead -in period (V601) is optional and may occur any ti me 
prior to Visit 1.   
The screening period spans the time between Visit [ADDRESS_943453]  a blood sample for plasma phosphorylated tau (P -tau). The P -tau assay is 
an investigational device. Participants  who do not meet the MMSE screening criteria are not to 
have  any other screening procedures performed. For  rescreening instructions, see Section  5.5. 
Participants  who meet both MMSE and plasma P -tau screening criteria (where available)  or have 
other evidence of AD  pathology  (approved by [CONTACT_3211])  may proceed to the remaining V1 
screening procedures once they have given  signed  or dated informed consent for the full study. 
Plasma P-tau testing may not be available at all location s for scre ening purposes . At these sites, a 
P-tau blood sample should still be collected and submitted. In such cases, only MMSE criteria 
must be met to proceed to V1.  
Approved on [ADDRESS_943454] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
38 
 For V1, o nce the full informed consent is signed, 63 days are allowed for completion of the 
remain ing Visit 1 screening assessments and procedures, as described in the SoA (Section 1.3). 
For those  who do not complete V601 prior to signing full study consent and proceed  directly to 
V1, MMSE and CDR screening criteria will need to be met before proceeding to have blood 
samples collected for plasma P-tau, other lab testing , and performing other cognitive 
assessments . The MRI and flortaucipir F18 PE T scans are to  be performed only after the 
participant meets all other eligibility criteria in the complete  screening  visit (V1) . For sites at 
which  P-tau testing will not be available as a screening  procedure , it will not be a protocol 
deviation  to contin ue with flortaucipir F18 PET scan ning without meeting the P-tau screening 
criteri on. In such cases , P-tau results will not be require d for randomization and enrollment  if all 
other screening criteria are met . Although imaging may be the last screening procedures of the 
study, it is expected that the  centrally read results will be available within the timeframe of [ADDRESS_943455] been reviewed by [CONTACT_27404], and the investigator or 
qualified  designee has confirmed that the participant  is eligible to be randomized. Only then can 
the participant proceed to Visit 2.   
4.1.2.  Double -Blind Period 2a (V2 -21)  
The treatment period 2a is a double -blind treatment phase beginning at Visit 2 (randomization).  
At Visit 2, appointments should be made for all remaining visits and should be scheduled as 
close as  possible to the target date, relative to Visit 2. Participants  who meet entry criteria and 
proceed to Visit 2 will be enrolled  and randomized to receive up to  124 weeks of treatment with 
LY3372689 low dose, LY3372689 high dose, or placebo.  During this double -blind period, 
participants will take study drug tablets once daily as dispensed.  Assessments and procedures 
will be performed as indicated in the SoA (Sect ion 1.3). Procedures  for some visits may take 
more than [ADDRESS_943456] visit with final assessments occur ring at week 76 (V21).  Sites 
will be notified if a participant at their site is to have their study completion visit at week 76, 
otherwise all participants should continue to study Period 2b (V22 -29). 
4.1.3.  Double -Blind Period 2b (V22 -29)  
All participants other than the last enrolled  participant , who has a study completion visit at  V21, 
will continue with assessments and procedures as indicated in the SoA  for Study Period 2b. The 
final visit for participants in Study Period 2b will occur when the last enrolled participant that 
has not  discontinued from the study completes their V21 study completion visit. At that time, all 
participants in study Period 2b w ill undergo  a study completion visit (end-of-study ET visit) at 
their next scheduled visit (following the instructions for the Period 2b ET visit) as described in 
the SoA and Manual of Operations. Study sponsor will notify sites when the last enrolled 
Approved on [ADDRESS_943457] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
39 
 participant achieves study completion V21, to enable scheduling of end of study ET visits for 
Period 2b.  End-of-study ET visits will follow assessments as indicated by [CONTACT_695440] 
2b (see SoA; Section 1.3). 
4.1.4.  Follow -up (V801)   
Participants are to return to the site for safety follow -up visit (Visit 801) 4 weeks ±[ADDRESS_943458] double -blind treatment visit has occurred. Assessments are to be performed as indicated 
in the SoA (Section 1.3). 
4.1.5.  Post-Treatme nt Safety Follow -up Period  (V802 and V 803)  
Participants  will be offered the opportunity to participate in the post-treatment safety follow -up 
period. Participants are to return to the site for post-treatment  safety  follow -up visit which l asts 
for approximately 12  weeks and starts at V isit 802. Assessments are to be performed as indicated 
in the SoA (Section 1.3.4 ). 
4.2. Scientific Rationale for Study Design   
Study MTAE is a multice nter, randomized, double -blind, placebo -controlled study of 
LY3372689 in participant s with early symptomatic AD, MMSE [ADDRESS_943459] -global score of 0.5 -
1.0, with cerebral tau burden that is elevated, as measured by [CONTACT_560452]  F18. For the purposes 
of this s tudy, early symptomatic AD is defined as those with mild cognitive impairment due to 
AD or mild Alzheimer’s dementia , consistent with Stages 2 through 4 of the FDA draft guidance 
entitled “ Early Alzheimer’s Disease: Developi[INVESTIGATOR_76508] . Guidance for Industry ” 
(February 2018; https://www.fda.gov/media/110903/download ) and the NIA-AA Research 
Framework: Toward a biological definition of Alzheimer’s disease . (Jack et al . 2018).  
Study MTAE includes a placebo treatment arm and allows all participant s to continue their AD 
standard -of-care concomitant medications. The use of a placebo comparator in Study MTAE is 
needed to determine the efficacy and safety of LY3372689 therapy. Inclusion of a placebo 
treatment arm is acceptable in Study MTAE becau se there are no available disease -modifying 
anti-tau treatments for AD; this approach is in agreement with the use of placebo described in the 
Declaration of Helsinki ( WMA 2013).   
The study includes a screening visit, which can last up to [ADDRESS_943460] plasma tau (where available) and flortaucipir 
F18 PET imaging results consistent with the presence of elevated tau pathology in order to be 
randomized to the double -blind period. A co mmon close study design is used to maximize 
efficiency  by [CONTACT_695441]. This is intended to result in increased likelihood of detecting 
LY3372689 effects  on study endpoints while minimizing overall study length and number of 
enrolled participants .  
See Section 8.[ADDRESS_943461] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
40 
 is hypothesized that the reduction of tau aggregation and further propagation may slow clinical 
decline.  
4.3. Justification for Dose   
Doses of 0.75 mg QD (low do se) and 3 mg QD (high dose) are being administered  to assess a 
comparison of efficacy and safety compared to placebo in this study.  The dose justification for 
the study  rests on characteristics of the nonclinical safety and pharmacology profile , and 
pharmacokinetic ( PK), pharmacodynamic ( PD), and safety findings in healthy human volunteers.  
Specifically, OGA EO was assessed in the brain of healthy participant s using  a novel PET 
radiotracer [18F] LSN3316612 after single oral doses of LY3372689  ranging from 0.25 to 0.5 
mg, and after once daily dosing of 1 mg for 14 days.  There was a  dose- and concentration -
dependent change in OGA brain EO , which was maintained with multiple dosing up to 14 days. 
Based on PK /PD modeling, a dose of 0.75 mg is predicted to achieve at trough a median EO of 
84% with a 62% probability of achieving 80% , and 3 mg is predicted to achieve at trough a 
median EO of 95% with a 98% probability of achieving 80% EO . To note, brain EO of 80% was 
shown in preclinical animal models to reduce tau pathology  and used as a benchmark to optimize 
doses for this clinical trial in AD participant s. 
Overall, doses of 0.75 and 3  mg once daily were selected  because both doses are predicted to 
achieve  at trough an EO of >80%. The lower dose has the potential for improved safety profile 
relative to a higher dose  based on nonclinical toxicology findings  (Section  2.2.1 ), with the higher 
dose of [ADDRESS_943462] the OGA hypothesis . Furthermore, 3 mg in this study is less than t he top dose of 
16 mg in the single ascending dose study and 7 mg in the MAD  study  studies ( Section  2.2.2 ), 
which in both studies did not demonstrate any dose -limiting AEs.  
If during study conduct the external DMC  recommends dose reduction at the study arm level, the 
high-dose arm could be reduce d to 1.5 mg (Section 6.6).  
4.4. End of Study  Definition   
A participant is considered to have completed the study if he  or she has completed all required 
phases of the study including the last visit  or the last scheduled procedure shown in the SoA . 
Approved on [ADDRESS_943463] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
41 
 5. Study Population   
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
Early symptomatic AD participant s, as defined in the inclusion criteria ( Section 5.1), will be 
enrolled into Study MTAE . The inclusion criteria ensure  that participants meet clinical criteria 
for having an AD clinical syndrome and hav e biomarker evidence consistent with the presence of 
AD pathology (Jack  et al. 2018) . With the  use of  tau PET  imaging , with or without plasma P -
Tau levels,  as part of the eligibility criteria , enrolled participants will be highly likely to meet 
pathological criteria for  AD, including the presence of both key pathologies, brain amyloid 
plaque and aggregated tau neurofibrillary tangles. ( Fleisher et al. 2020; Palmqvist et al. 2020) . 
This study  population is hypothesized to represent those that will most benefit from the 
mechanism of action of LY3372689, which is believed to reduce further accumulation  of 
pathological tau but not remove existing tau ; furthe r, a population at the earlie r stage s of tau 
pathology may benefit the most from LY3372689 treatment. It is also necessary to enroll a 
population that is likely to demonstrate clinical decline in the timeframe  of Study MTAE . 
Elevated levels of tau pathology have been associated with increased risk for clinical progression  
(Pontecorvo  et al. 2019) . Therefore,  the inclusion criteria for Study MTAE are selected to 
identify a  study population with known  tau pathology  targeted by [CONTACT_36940]337 2689 , at levels 
consistent with risk of  short -term clinical progression.   
5.1. Inclusion Criteria   
Participant Characteristics  
[1] Men or women (not of childbearing potential),  60 to 85 years of age.  
a. Female participant s are considered women not of childbearing potential if  
 they have a congenital anomaly , such as Mullerian agenesis , or  
 they are infertile due to surgical sterilization (e.g., hysterectomy , or at least [ADDRESS_943464] -surgical bilateral oophorectom y or tubal ligation) , or  
 they are post -menopausal.  
b. The post -menopausal state is defined as  
i. a woman [ADDRESS_943465] 55 years of age with a diagnosis of menopause prior to 
starting hormone replacement therapy.  
[2] Gradual and progressive change in memo ry function reported by [CONTACT_695442] ≥6 months.   
[3] MMSE 22 -30 (inclusive) .  
[4] CDR global score of 0.5 to 1.0 (inclusive) , with a memory box score ≥0.5 .   
[5] Meet plasma P -tau criter ia (where available  for screening  purposes ). The acceptance of a 
historical evidence of positive AD pathology  in the place of plasma P -tau is at the discretion 
of the sponsor.   
Approved on [ADDRESS_943466] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
42 
 [6] Meet flortaucipir F18 PET scan criteria. A historical flortaucipir F18 PET scan may be 
submitted to be considered for eligibility if performed within 6 months of randomization. The 
acceptance of a historical scan is at the discretion of the sponsor.   
[7] Have a study partner who will provide written informed consent to participate, is in frequent 
contact [CONTACT_625889] (defined as at least 10 h per week), and will accompany the 
participant to study visits or be available by [CONTACT_616154].  
A second study partner may serve as backup. The study partner(s) is (are) required to 
accompany the participant  for signing consent. One study partner is requested to be present 
on all days the C -SSRS is administered and must be present on all days the cognitive and 
functional scales are administered. If a participant  has a second study partner, it is pr eferred 
that [ADDRESS_943467] a study partner available by [CONTACT_695443] a visit for the following assessments:  
 AEs and conc omitant medications , and  
 relevant portions of the C -SSRS  
If a study partner must withdraw from study participation, a replacement may be allowed at the 
investigator’s discretion. The replacement will need to sign a separate informed consent on the 
first vi sit that he or she accompanies the participant.   
[8] Are reliable and willing to make themselves available for the duration of the study and are 
willing to follow study procedures.  
[9] Males who agree to use effective methods of contraception may participate in this 
trial. 
Contraception  
a. Male  participant s 
(i). should refrain from sperm donation for the duration of the study 
and until [ADDRESS_943468] dose of study drug.  
(ii). regardless of their fertility status, with nonpregnant female 
partners of childbearing potential , must agree to either remain 
abstinent (if this is their preferred and usual lifestyle) or use 
condoms with spermicide during intercourse for the duration of 
the study and for 92 days after study drug dosing.  
(iii). who are in e xclusively same sex relationships (as their preferred 
and usual lifestyle) are not required to use contraception.  
 [10] If taking a commercially approved prescription medication for the treatment of AD, 
have received treatment with a stable dose for at lea st 1 month before screening  
(V1) . If approved prescription medication for AD is a disease -modifying therapy  
(e.g., anti-amyloid or anti -tau), then have received treatment with a stable dose for 
at least [ADDRESS_943469] 2  months or >5 
half-lives (whichever is longer) of the medication before randomization.  
Approved on [ADDRESS_943470] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
43 
 [11] Changes in concomitant medications that could potentially affe ct cognition and their 
dosing should be stable for at least 1 month before screening, and between screening 
and randomization (does not apply to medications discontinued due to exclusions or 
with limited duration of use, such as antibiotics).  
Informed  Cons ent 
[12] Capable of giving signed informed consent as described in Section 10.1.3 , which includes 
compliance with the requirements and restrictions listed in the ICF and in this protocol.  
5.2. Exclusion Criteria   
[13] Lack, in the investigator’s opi[INVESTIGATOR_1649], of adequate premorbid literacy, adequate vision, 
or adequate hea ring to complete the required psychometric tests.  
[14] Significant neurological disease affecting the CNS, other than AD, that may affect 
cognition or ability to complete the study, including but not limited to , other 
dementias, serious infection of the br ain, Parkinson’s disease, multiple concussions, 
or epi[INVESTIGATOR_541421] (except febrile childhood seizures).  
[15] Current serious or unstable illnesses including cardiovascular, hepatic, renal, 
gastroenterological , respi[INVESTIGATOR_696], endocrinologic (in cluding unstable diabetes), 
neurologic (other than AD), psychiatric, immunologic, or hematologic disease and 
other conditions that, in the investigator’s opi[INVESTIGATOR_1649], could interfere with the analyses 
in this study; or has a life expectancy of <24  months.  
[16] History of cancer within the last 5 years, with the exception of nonmetastatic basal 
and/or squamous cell carcinoma of the skin, in situ cervical cancer, nonprogressive 
prostate cancer, or other cancers with low risk of recurrence or spread.  
[17] Particip ants with any current primary psychiatric diagnosis other than AD if, in the 
judgment of the investigator, the psychiatric disorder or symptom is likely to 
confound interpretation of drug effect, affect cognitive assessment, or affect the 
participant ’s ability to complete the study. Participant s with a history of 
schizophrenia or other chronic psychosis are excluded.  
[18] Are clinically judged by [CONTACT_695444], or examination .  
[19] History of alcohol or drug abuse disorder (except tobacco use disorder) within 2 
years before the screening visit.  
[20] Known positive serologic findings for human immunodeficiency virus antibodies. 
Local laws and regulations may apply to whether testing i s required.  
[21] Participant s with a past history (suspected or confirmed) of Hepatitis B should have 
HBsAg testing at screening and are excluded if HBsAg is positive.  
[22] Participant s with a past history (suspected or confirmed) of Hepatitis C (resolved >6 
months prior to enrollment) should have HCV RNA PCR testing at screening and 
are excluded if the HCV RNA PCR test is positive.  
Approved on [ADDRESS_943471] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
44 
 [23] History of clinically significant multiple or severe drug allergies, significant atopy, 
or severe posttreatment hypersens itivity reactions (including but not limited to 
erythema multiforme major, linear immunoglobulin A dermatosis, toxic epi[INVESTIGATOR_7387], and/or exfoliative dermatitis).  
Imaging,  Vital Signs, Electrocardiograms, Laboratory Tests, and Physical Examination  
[24] Have any clinically important abnormality at screening, as determined by [CONTACT_1275], in physical or neurological examination, vital signs, ECG, or clinical 
laboratory test results that could be detrimental to the participant , could 
compromise th e study, or show evidence of other etiologies for dementia.  
[25] Screening MRI that shows evidence of significant abnormality that would suggest 
another potential etiology for progressive dementia or a clinically significant 
finding that may impact the participant ’s ability to safely participate in the study.  
[26] Have any contraindications for MRI, including claustrophobia or the presence of 
contraindicated metal (ferromagnetic) implants/cardiac pacemaker.  
[27] Sensitivity to flortaucipir F18.  
[28] Contrai ndication to PET and present or planned exposure to ionizing radiation that, 
in combination with the planned administration of study PET ligands, would result 
in a cumulative exposure that exceeds local recommended exposure limits.  
[29] Cardiovascular scre ening ECG criteria  
 heart rate less than 45 beats/min  
 Mobitz type [ADDRESS_943472] -degree  AV block (uncorrected by 
[CONTACT_695445]) , and  
 ECG with QTc >450 msec in males and >470 msec in females .  
[30] Calculated creatinine clearance <30 mL/min (Cockcroft –Gault formula; Cockcroft 
and Gault 1976) at screening.  
[31] ALT ≥[ADDRESS_943473] ≥[ADDRESS_943474], TBL ≥[ADDRESS_943475], or 
ALP ≥[ADDRESS_943476] at screening.  
NOTE: Participant s with TBL ≥[ADDRESS_943477] are not excluded if they meet all of 
the following criteria for Gilbert syndrome:  
a. bilirubin is predominantly indirect (unconjugated) at screening 
(direct bilirubin within normal limits).  
b. absence of liver disease.  
c. ALT, AST, and ALP ≤1x ULN at screening.  
d. hemoglobin is not significantly decreased at screening.  
Prior/Concomitant Therapy  (Refer to Manual of Operations for complete lists)  
[32] Have known allergies to LY3372689, related compounds, or any components of the 
formulation; or history of significant atopy.  
Approved on [ADDRESS_943478] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
45 
 Prior/Concurrent Clinical Trial Experience  
[35] Are currently enrolled in any other interventional clinical trial involving an 
investigational product or any other type of medical research judged not to be 
scientifically or medically compatible with this study.  
[36] Have participated within the last [ADDRESS_943479] is scientifically or 
medically incompatible with this study (such as an anti -tau or anti -amyloid therapy)  
and has a long half -life, 3 months or 5 half -lives (whichever is longer) should have 
passed prior to screening . Participation in observational studies may be permitted 
upon review of the observational study protocol and approval by [CONTACT_456] . 
Other Exclusions  
[37] Are investigator site personnel directly  affiliated with this study and/or their 
immediate families. Immediate family is defined as a spouse, parent, child, or 
sibling, whether biological or legally adopted.  
[38] Are Lilly employees or are employees of TPOs involved in the study who require 
exclusion of their employees, or have study partners who are Lilly employees or are 
employees of TPOs involved in a study that requires exclusion of their employees.  
[44] Criterion deleted . 
[45] Criterion d eleted . 
[46] Criterion deleted . 
5.3. Post-Treatment Safety Follow -up Period   
Exclusion criteria  
[47] Are currently enrolled in any other interventional clinical tria l involving an investigational 
product or any other type of medical research judged not to be scientifically or medically 
compatible with this study.  
5.4. Lifestyle Considerations   
Participant s should refrain from donating blood or blood products from the time of their 
screening visit until [ADDRESS_943480] 2024 GMT
CCI
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
46 
 5.5. Scre en Failures   
Screen failures are defined as participant s who consent to participate in the clinical study  but are 
not subsequently enrolled  in the study . A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participant s to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory 
author ities. Minimal information includes demography, screen failure details, eligibility criteria, 
and any SAE .  
If the screen failure is due to a  CDR global  score <0.5, or due to non-eligible plasma P-tau or 
flortaucipir  F18 PET scan , then [ADDRESS_943481] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943482] (s) or medical device (s) intended to be 
administered to  or used by  a study participant according to the study protocol.  
6.1. Study Intervention(s) Administered   
Treatment Regimens, Double -Blind Treatment Period   
LY3372689 Dose (mg)  Regimen  
0.75 LY33 [ZIP_CODE] : 0.75 mg dose once daily  for up to  124 weeks (minimum of 76 
weeks) (Visit 2 [Week 0] –Visit 29 [Week 1 24]). 
3.0a 
 LY3372689: 3 .0 mg dose once daily  for up to 124 weeks (minimum of 76 
weeks) (Visit 2 [Week 0] –Visit 29 [Week 1 24]). 
Placebo  
 Placebo dose once daily  for up to 124 weeks (minimum of 76 weeks) (Visit 2 
[Week 0] –Visit 29 [Week 124]).  
a Dose may be reduced from 3 to 1.5  mg if deemed necessary . Refer to Section  6.6. 
Investigational products used in this study are:  
 LY3372689 , and  
 Placebo . 
Investigational product s are administered orally  once daily  in the morning at approximately the 
same time each day . LY3372689  may be taken with or without food . All LY3372689 strengths 
and placebo will be identical tablets . 
This study will utilize a [ADDRESS_943483] enrolled participant  that has not discontinued from treatment has 
achieved 76 weeks of assigned treatment . The maximum duration of treatment is 124 weeks.  
The table below lists the study  interventions  used in this clinical study.  
Intervention  Name  [CONTACT_36940]3372689  Placebo  Flortaucipir  F18 
Authorized as defined by [CONTACT_695446]. Clinical trial materials will be labeled according to the country’s 
regulatory requirements. All IPs will be stored, inventoried, reconciled, and destroyed according 
to applicable regulations. Clinica l trial materials are manufactured in accordance with current 
Good Manufacturing Practices.  
Approved on [ADDRESS_943484] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
48 
 6.2. Preparation/Handling/Storage/Accountability   
1. The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all IP received and any discrepancies are reported and 
resolved before use of the IP. 
2. Only participants enrolled in the study may receive IP, and only authorized site staff or 
designee may supply or administer IP. All study intervention must be stored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accor dance 
with the labeled storage conditions with access limited to the investigator and authorized 
site staff  or designee . 
3. The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for IP accountability, reconcil iation, and record maintenance (i .e., receipt, 
reconciliation, and final disposition records).  
4. Further guidance and information for the final disposition of unused IP are provided by 
[CONTACT_456].  
6.3. Measures to Minimize Bias: Randomization and Blinding   
This is a double -blind study  (study period s 2a and 2b) , with design to maintain blinding to 
treatment. To preserve the blinding of the study, a minimal number of Lilly p ersonnel will see 
the randomization table and treatment assignments before the study is complete.   
For between -group comparability, participant randomization will be stratified by [CONTACT_198373], tau burden (moderate versus high) as defined by [CONTACT_695447], and by [CONTACT_695448] -modifying therapy for AD.  Enrollment of high tau burden 
participants will be capi[INVESTIGATOR_299584] a predetermined proportion of the total enrolled population. 
Hence, study eligibility based on flor taucipir PET scan results may change as the study 
progresses. Assignment to treatment groups will be determined using an interactive web 
response system ( IWRS ). The IWRS will be programmed using the dynamic allocation 
(minimization) method of Pocock and Si mon (1975), to balance the treatment arms using three 
factors: investigative site, tau burden, and prior or current use of any approved disease -
modifying therapy for AD. This is to achieve balanced participant  assignment between treatment 
arms as much as p ossible within each stratum and at the study level.  Randomization into [ADDRESS_943485] obtain specific approval from a 
Lilly -designated Medical Monitor  for the  participant to continue in the study.  
In case of an emergency, the i nvestigator has the sole responsibility for determining if unblinding 
of a participant ’s treatment assignment is warranted for medical management of the event. The 
participant ’s safety must always be the first consideration in making such a determination. If a 
participant ’s treatment assignment is unblinded, Lilly must be notified immediately. If the 
Approved on [ADDRESS_943486] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
49 
 investigator decides that unblinding is warranted, it is the responsibility of the investigator to 
promptly document the decision and rationale and notify Lill y as soon as possible.  
Participant s who meet all criteria for enrollment will be assigned a study ( participant ) number at 
Visit 601 or Visit 1 and randomized to double -blind treatment at Visit 2. Participant s will be 
randomized to LY3372 689 low dose , LY337 2689  high dose , or Placebo in a 1:1 :[ADDRESS_943487] questioning 
and/or counting returned tablets. The participant  should be instructed to retai n all empty drug 
packages after using up the medication in the package and to bring the empty packages and any 
unused medication to the clinic at each visit so that the clinic staff can record the amount of 
medication used since the last visit.  
Compliance  for the double -blind study period s will be assessed at telephone visits via 
questioning of the participant  and/or study partner.  
The administration of all study medication should be recorded in the appropriate sections of the 
eCRF.  
Participant s who consum e 80-100% of the prescribed daily dose during this study will be 
considered compliant. A participant  will be considered significantly noncompliant if he or she is 
judged by [CONTACT_695449]. Participant s regarded as non -compliant may be discontinued at 
the investigator’s discretion, in consultation with the Lilly -designated Medical Monitor . 
6.5. Concomitant Therapy   
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollment or receives 
during the study must be recorded in the CRF, along with any changes to dose.   
The Lilly -designated Medical Monitor  should be contact[CONTACT_61519].  
Participant s and their study partners will be instructed to consult the investigator or other 
appropriate study personnel at the site before initiation of any new medications or supplements 
and before changing dose of any current concomitant medications or supplements.  
Use of benzodiazepi[INVESTIGATOR_430514] -needed basis  for insomnia or daily dosing as 
anxiolytics is permitted. Use of sedatives or hypnotics should be avoided for 8 h before 
administration of the cognitive and functional tests unless they are given chronically.  
The following are prohibited concomitant medic ations during the study  (refer to Manual of 
Operations for complete lists) : 
Approved on [ADDRESS_943488] 2024 GMT
CCI
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
50 
  Use of any investigational drug or device not specified in this study unless approved by 
[CONTACT_11008] -designated medical monitor (topi[INVESTIGATOR_695415])   
 Use of any drug of abuse, including but not limited to illicit amphetamine, cocaine, illicit 
opi[INVESTIGATOR_858], propoxyphene, methadone, methaqualone, phencyclidine, and illicit barbiturate . 
 Use of cannabis in a pattern of abu se.  
6.5.1.  Standard of Care for Alzheimer’s Di sease   
To ensure standard of care for AD, use of approved prescription treatments for AD is permitted 
(but not a require ment ) in this study. The section below provides additional guidance on 
managing concomitant medication use.  
Double -Blind Period  (Period 2a and 2b)  
Use of approved or standard -of-care treatments for AD is permitted (but not a require ment ) 
during the study, provided that the dose has been unchanged for 1 month before Visit 1. If 
approved prescription  AD medication is a disease -modifying  therapy  (e.g., anti-amyloid or anti -
tau), then dose must be stable for at least 3 months prior to V2 . Doses of these medications 
should remain constant when possible,  throu ghout the double -blind period (Visit 2 to 29). Any 
initiation o r changes to standard -of-care medications should be done in consultation with the 
sponsor prior to implementing to determine if the participant  would be allowed to continue in the 
study . 
Nonmedication treatments for AD such as behavioral management are permitted but are subject 
to the same restrictions as medication treatment taken for AD.  
Post-treatment Safety Follow -up Period  (V802 and V803) 
Use of approved or standard -of-care treatments  including both symptomatic and disease -
modifying therapi[INVESTIGATOR_695416]-treatment safety follow -up period . Any 
changes to concomitant medication should be documen ted. Any concomitant medication used 
should be approved and used per the d irection of the  prescribing information.  
6.6. Dose Modification   
Dose modification of IP will be permitted for notable treatment -emergent AEs and AEs of 
special interest  as determined by [CONTACT_695450] , or as determined by [CONTACT_695451].  Sponsor , site staff, and study participant  will remain 
blinded to treatment  assignments in all cases.  A one -time dose reduction can be applied  in a 
blinded fashio n after  sponsor  safety review  and/or an external DMC  review  (blinded or 
unblinded)  on a case -by-case basis . Individual case dose reductions will result in individual 
participant reductions from 3.[ADDRESS_943489] 2024 GMT
CCI
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
51 
 team, participants , and blinded  site staff will remain blinded to study dose and treatment arm in 
the event of dose reduction s. In addition, treatment can be temporarily discontinued as an 
alternative to a dose reduction (see Section 7.1.1 ). 
6.7. Intervention  after the End of the Study  
Study intervention will not be made available to participants  after conclusion of the study.  
 
 
Approved on [ADDRESS_943490] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
52 
 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal   
7.1. Discontinuation of Study Intervention   
In rare instances, it may be necess ary for a participant to permanently discontinue IP. If IP is 
permanently discontinued, the participant may remain in the study (following the SoA, except as 
noted below) to be evaluated for safety and efficacy . 
See the SoA (Section 1.3) for data to be collected at the time of intervention discontinuation for 
ET procedures and follow -up and for any further evaluations that need to be completed.   
Participants  who permanently d iscontinued from IP but remain in the study  should complete ET 
procedures (as indicated in the SoA ), then continue to participate in subsequent scheduled visits 
and assessments, as appropriate . After ET  visit, PK assessments should not be collected  in 
participants that have permanently discontinued from IP . 
Investigational product may be discontinued for a participant for the following reasons (details 
given below):   
 clinical judgment  
 AEs 
 by [CONTACT_541447]’s designee ( e.g., legal guardian)  
 severe noncompliance  
 the participant re quires an excluded therapeutic agent  and temporary discontinuation 
criteria cannot be met , and  
 pacemaker that is not MRI -compatible . 
Clinical Judgment  
AE or clinically significant laboratory value, ECG result, physical examination finding, MRI 
finding (such as symptomatic ischemic stroke), C -SSRS result, or vital sign measurement of such 
severity that, in the opi[INVESTIGATOR_695417] -designated  Medical Monitor, continued 
treatment is not in the best interest of the participant . 
Hepatic Event or Liver Test Abnormality  
Participants who are discontinued from IP due to a hepatic event or liver test abnormality should 
have additional hepatic safety d ata collected via  the CRF . 
Discontinuation of the IP for abnormal liver tests  should be  considered by [CONTACT_82378] 
a participant meets 1 of the following conditions after consultation with the Lilly -designated 
Medical Monitor:   
 ALT or AST >[ADDRESS_943491]   
 ALT or AST >[ADDRESS_943492] for more than 2 weeks   
 ALT or AST >[ADDRESS_943493] and TBL >[ADDRESS_943494] or INR >1.5    
 ALT or AST >[ADDRESS_943495] with the appearance of fatigue, nausea, vomiting, right upper -
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)   
 ALP >[ADDRESS_943496]   
 ALP >2.[ADDRESS_943497] and TBL >[ADDRESS_943498] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
53 
  ALP >2.[ADDRESS_943499] with the appearance of fatigue, nausea, vomiting, right quadra nt pain or 
tenderness, fever, rash, and/or eosinophilia (>5%)   
C-SSRS  
In addition, IP may be discontinued if participants:  
 Answer “yes” to Question 4 or Question 5 on the “Suicidal Ideation” portion of the C -SSRS, 
or 
 Answer “yes” to any of the suicide -related behaviors on the Suicidal Behavior portion of the 
C-SSRS.  
A psychiatrist or appropriately trained professional may assist in the decision to discontinue the 
participant.   
ECG  
If a clinically significant finding is identified (including, but not limit ed to changes from baseline 
in QT interval corrected using QTcF , PR interval or new onset AV block ) after enrollment, the 
investigator or qualified designee will determine if the participant can continue in the study and 
if any change in participant management is needed. This review of the ECG printed at the time of 
collection must be documented. Any new clinically relevant finding should be reported as an AE.  
Severe Noncompliance  
Severe noncompliance to the study protocol, that results in  a safety concern, in the judgment of 
the investigator, may be reason for discontinuing IP.  
Excluded Therapeutic Agent  
The participant , for any reason, requires a treatment with an excluded therapeutic agent 
(Section  6.5) and temporary discontinuation criteria cannot be met (see Section  7.1.1 ). 
Pacemaker that is not MRI -compatible  
Participant s who require a ferromagnetic implant or insertion of a cardiac pacemaker that is not 
MRI -compatible will be discontinued from IP and may remain in the study off IP  with no  further 
MRIs.  
7.1.1.  Tem porary Discontinuation   
Treatment can be temporarily discontinued (examples include short -term treatment using a 
prohibited drug, uncertain AE, hospi[INVESTIGATOR_059]).  Re-starting investigational product is based on 
Sponsor and the Principal Investigator's judgment. The maximum permissible treatment 
suspension is a total of 6 weeks over the duration of the study. Temporary treatment 
discontinuation and restarting needs to be documented. If temporary discontinuation is due to an 
AE, it should be  reported to the Lilly -designated Medical Monitor . 
7.2. Participant Discontinuation/ Withdrawal from the Study   
A participant may withdraw from the study:   
 at any time at his/her own request  
 at the request of his/her designee ( e.g., legal guardian)  
Approved on [ADDRESS_943500] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
54 
  at the discretion of the investigator for safety, behavioral, compliance, or administrative 
reasons  
 if the participant becomes pregnant during the study  
 if the participant enrolls in any other clinical study involving an investigational 
medicinal product or enrollment in any other type of med ical research judged not to be 
scientifically or medically compatible with this study , and  
 if participation in the study needs to be stopped for medical, safety, regulatory, or other 
reasons consistent with applicable laws, regulations, and GCP . 
At the tim e of discontinuing from the study, if possible, an E T visit should be conducted, as 
shown in the SoA. See SoA for data to be collected at the time of study discontinuation and 
follow -up and for any further evaluations that need to be completed. The participant will be 
permanently discontinued both from the I P and from the study at that time.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent. If a participant 
withdraws from the study, he  or she may request destruction of any samples taken and not tested, 
and the investigator must document this in the site study records.  
7.2.1.  Discontinua tion of Inadvertently Enrolled Participants   
If the sponsor or investigator identif ies a participant  who did not meet enrollment criteria and 
was inadvertently enrolled, then the participant  should be discontinued from study treatment . 
Safety follow -up should be performed as outlined in Se ction 1.3 (Schedule of Activities), Section 
8.2 (Safety Assessments), and Section 8.3 (Adverse Events and Serious Adverse Events , and 
Product Complaints ) of the protocol.   
7.3. Lost to Follow -up  
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298]. Site personnel or designee are 
expected to make diligent attempts to contact [CONTACT_10971] a scheduled visit 
or were otherwise unable to be followed up by [CONTACT_779].   
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 1  
(Section 10.1). 
Approved on [ADDRESS_943501] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
55 
 8. Study Assessments and Procedures   
● Study procedures and their timing are summarized in the SoA.  Protocol  waiver s 
or exemptions are not allowed.  
● Immediate  safety concerns  should be discussed with the s ponsor immediately 
upon occurrence or awareness to determine if the participant should continue or 
discontinue study intervention . 
● Adherence to the study design requirements, including those specified in the SoA, 
is essential and required for study condu ct. 
● All screening evaluations must be completed and reviewed to confirm that  
potential participant s meet all eligibility criteria. The investigator will maintain a 
screening log to record details of all participant s screened and to confirm 
eligibility or record reasons for sc reening failure, as applicable.   
8.1. Efficacy Assessments   
Cognitive and functional testing data will be documented  using an eCOA tablet. The audio voice 
recordings of the rater’s questions and the participant ’s and study partner’s responses will also be 
collected via the eCOA tablet during administration of the cognitive and functional testing for 
central monitoring o f rater scale administration. Cognitive and functional testing for each 
participant  should be performed at approximately the same time on each day, whenever possible, 
to reduce potential variability.  
Note that the CDR  should  be administered by a different  rater than the ADAS -Cog [ADDRESS_943502] assessment . 
When administered, cognitive and functional testing should be performed before medical 
procedures that could be stressful for the participant  (e.g., blood draws). Note that some 
procedures ( e.g., MRI, flortaucipir F18 PET imaging ) can be conducted on other days within the 
visit window.  
8.1.1.  Primary Efficacy Assessment   
The iADRS (Wessels et al. 2015) represents a composite that was developed using b oth a theory -
driven approach (incorporating measures of both cognition and function) and a data -mining 
approach (identifying the most sensitive combination of scales through analysis of data from the 
Alzheimer’s Disease Neuroimaging Initiative and the EXPE DITION, EXPEDITION2, and 
EXPEDITION3 studies).  
The iADRS is a simple linear combination of scores from [ADDRESS_943503] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
56 
 The iADRS score will be der ived from the ADAS -Cog 13 and the ADCS -iADL. The 
ADAS -Cog 13 and the ADCS -ADL will be the actual scales administered to participants.  
8.1.2.  Secondary Efficacy Assessments   
[IP_ADDRESS].  MMSE   
The MMSE is a brief instrument used to assess cognitive function in participant s (Folstein et al. 
1975). The instrument measures orientation, memory, and attention; the ability of the partic ipant 
to name [CONTACT_272755]; follow verbal and written commands; write a sentence; and copy figures. The  
range for the total MMSE score is 0 to 30, with lower scores indicating greater level of  
impairment.  
[IP_ADDRESS].  ADAS -Cog 13  
The ADAS -Cog 13 is a rater -administered instrument that was designed to assess the severity of 
dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD 
(Rosen et al. 1984). The ADAS -Cog [ADDRESS_943504] typi[INVESTIGATOR_272725]: orien tation, verbal memory, 
language, praxis, delayed free recall, digit cancellation, and maze -completion measures (Mohs et 
al. 1997). The ADAS -Cog 13 scale ranges from 0 to 85, with higher scores indicating greater 
disease severity.  
[IP_ADDRESS].  CDR -Sum of Boxes   
The CDR -SB is a semi -structured interview performed with the participant and study partner 
(informant) that integrates domains of cognition and function into a single overall score (Berg et 
al. 1992; Morris 1993). By [CONTACT_20526] a severity score for each of the 6 domains, and then 
summating each domain, a total score known as “Sum of Boxes” is obtained. Higher scores 
indicate greater disease severity.  
The CDR global ratings, calculated using an  algorithm, range from 0 (no dementia) to 3 (severe 
dementia) while CDR -SB scores, calculated by [CONTACT_541465], range from 0 to 18 (with 
higher scores indicative of more impairment).  The informant is queried about the participant’s 
memory, orientat ion, judgment and problem solving, community affairs, home and hobbies, and 
personal care. The participant’s memory, orientation, judgment, and problem -solving ability are 
assessed. This scale demonstrates acceptable psychometric characteristics (Coley et al. 2011; 
Cedarbaum et al. 2013) and has been shown to be sensitive enough to detect disease progression, 
even in populations with less advanced clinical disease (Williams et al. 2013; Wessels et al. 
2015).  
The CDR should be administered whenever possible by [CONTACT_695452]. The study partner and participant must be interviewed separately. 
The CDR must always be administered to the study partner first and then to the participant.  
Approved on [ADDRESS_943505] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
57 
 [IP_ADDRESS].  ADCS -ADL   
The ADCS -ADL is a 23 -item inventory developed as a rater -administered questionnaire that is to 
be answered by [CONTACT_2299] ’s study partner (Galasko et al. 1997, 2004). The ADCS -ADL 
should be admi nistered by [CONTACT_695453].  
The ADCS -ADL subset of items (items 6a and 7 to 23) for iADLs will be used as a secondary 
efficacy measure. The focus in the early symptomatic AD population is on the iADLs ra ther than 
the bADLs, which are thought to be affected in more severe stages of the disease. The range for 
the iADL score is [ADDRESS_943506] 4 weeks. If the participant  did attempt the ADL, the study partner is asked 
to rate the participant ’s performance level based on a set of performance descriptions. Scores for 
each item and the overall scor e for the tool are calculated. The range for the total ADCS -ADL 
score is 0 to 78, with lower scores indicating greater level of impairment. Separate scores for the 
bADLs (0 to 19) will also be computed.  
8.1.3.  Exploratory Assessments   
[IP_ADDRESS].  Digital Clock Drawing Test   
The traditional Clock Drawing Test is a well -established and widely used pen and paper 
cognitive assessment in which individuals draw the face of a clock showing a specific time on a 
blank page, then copy a pre -drawn clock. The Digital Clock Drawing Test r evises this familiar 
test by [CONTACT_695454] (Souillard -Mandar et al. 2016).  
Thus, the innovation offered by [CONTACT_695455].  
[IP_ADDRESS].  Digit Symbol Substitution Test   
The Digit Symbol -Coding test from the Wechsler Adult Intelligence Scale -IV (Wechsler et al. 
2008) engages multiple cognitive abilities, but most notably processing speed. The Digit 
Symbol -Coding is a paper and pencil test presented on a single sheet of paper t hat requires a 
participant to match symbols to numbers according to a key located on the top of the page. The 
participant copi[INVESTIGATOR_695418] a row of numbers. The number of correct 
symbols within the allotted time (120 s) constitutes the s core. Maximum coding total raw score is 
135 points.  
8.2. Safety Assessments   
Planned time points for all safety assessments are provided in the SoA  (Section  1.3). 
8.2.1.  Physical Examinations   
Physical examinations will be performed as indicated in the SoA (Section  1.3).  
The complete physical examination will include assessment of  
Approved on [ADDRESS_943507] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
58 
  general appearance  
 skin, head, eyes, and neck  
 lymph nodes  
 thyroid  
 abdom en (bowel sounds, liver , and spleen palpation)  
 back (costovertebral angle tenderness) , and 
 musculoskeletal, cardiovascular, and respi[INVESTIGATOR_27441].  
Neurological examinations will be performed as indicated in the SoA (Section  1.3).  
The examinations will include a thorough assessment of  
 gait 
 balance  
 coordination  
 cranial nerves  
 sensory and motor systems, and  
 reflexes.  
If necessary, given the training of the PI, a neurologist may be consulted in the event of 
significant new findings.  
If a clinically meaningful change in a n MRI is noted during the study, an additional full 
neurological exam should be performed as soon as  possible, along with any other medical 
follow -up deemed necessary by [CONTACT_093].  
8.2.2.  Vital Signs   
Vital signs, including temperature, will be measured at visits indicated in th e SoA  (Section 1.3). 
Vital signs may be repeated as needed.   
[IP_ADDRESS].  Blood Pressure   
Sitting blood pressure and pulse will be measured after approximately 5 min in the sitting 
position only, as indicated in the So A. In addition, orthostatic blood pressure and pulse will be 
measured supi[INVESTIGATOR_695419], as detailed in the SoA (Section 1.3). 
For orthostatic blood pressure monitoring, participants should be supi[INVESTIGATOR_1919] [ADDRESS_943508] 3 min prior to taking the respective measurements. If the participant  feels 
unable to stand, only supi[INVESTIGATOR_695420].  
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms.  
[IP_ADDRESS].  Height, Weight, and Body Temperature   
Height and body wei ght will be measured. Measurements should be taken, when possible, with 
the same scale for all measurements. Body mass index will be calculated from the height and 
body weight.  
Approved on [ADDRESS_943509] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
59 
 Temperature will be recorded using an oral or tympanic (or another  acceptable route) 
thermometer.  
Any body weight data entered into the CRF will be used for the overall data analysis . 
8.2.3.  Electrocardiograms   
For each participant , 12-lead digital ECGs will be co llected during the double -blind period, 
according to the SoA (Section  1.3). Participant s must be supi[INVESTIGATOR_17044] 5 to 10 min 
before ECG collection and remain supi[INVESTIGATOR_57966].  
Electrocardiograms may be obtained at additional times, whe n deemed clinically necessary.  
Collection of more ECGs (replicates) than expected at a timepoint is allowed when needed to 
ensure high -quality records.  
Electrocardiograms will initially be interpreted by a qualified physician (the investigator or 
qualifie d designee) at the site as soon after the time of ECG collection as possible, and ideally 
while the participant  is still present, to determine whether the participant  meets entry criteria at 
the relevant visit(s) and for immediate participant  management, s hould any clinically relevant 
findings be identified.  
After enrollment, if a clinically significant increase in the QT/QTc , PR, or AV block interval 
from baseline or other clinically significant quantitative or qualitative change from baseline is 
identifie d, the participant  will be assessed by [CONTACT_324010] (e.g., palpi[INVESTIGATOR_814], 
near syncope, syncope) and , in consulta tion with the spons or to determine whether the 
participant  can continue in the study. The investigator or qualified designee is  responsible for 
determining if any change in participant  management is needed. The investigator or qualified 
designee must document his/her review of the ECG printed at the time of evaluation.   
All digital ECGs will be electronically transmitted to a desi gnated central ECG laboratory. A 
cardiologist at the central ECG laboratory will then conduct a full overread. A report based on 
data from this overread will be issued to the investigative site. These data are not routinely 
reported back to the investigati ve site. All data from the overreads will be placed in the Lilly 
database for analytical and study report purposes.  
When there are differences in ECG interpretation between the investigator (or qualified 
designee) and the cardiologist at the central ECG la boratory, the investigator’s (or qualified 
designee’s) interpretation will be used for study entry and immediate participant  management.  
Interpretations from the cardiologist at the central ECG laboratory will be used for data analysis 
and report writing purposes.  
The investigator (or qualified designee) must document his/her review of the ECG printed at the 
time of collection, the final overread ECG report issued by [CONTACT_81131], and any 
alert reports.  
8.2.4.  Clinical Safety Laboratory Assessments   
● See Appendix [ADDRESS_943510] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
60 
 ● The investigator must review the laboratory report, document this review, and 
record any clinically relevant changes occurring during the study in the AE 
section of the case report form . The laboratory reports must be retained with 
source documents unless a Source Document Agreement or comparable document 
cites an electronic location that accommodates the expected retention duration . 
Clinically significant abnormal laboratory findings are those which are not 
associated with the underlying disease, unless ju dged by [CONTACT_163582]'s condition.  
● All laboratory tests with values considered clinically significantly abnormal 
during participation in the study or within the follow -up period after last dose of 
IP should be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by [CONTACT_695456] -designated Medical 
Monitor.  
○ If such values do not return to normal/baseline within a period of time judged 
reasonable by [CONTACT_093], the etiology should be identified and the sponsor 
notified.  
○ All protocol -required laboratory assessments, as defined in Appendix 2, must be 
conducted in accordance with the SoA , standard collect ion requirements and 
laborato ry manual . 
 If laboratory values from non -protocol -specified laboratory assessments performed at 
the institution’s local laboratory require a change in participant management or are 
considered clinically significant by [CONTACT_093] (e.g., SAE or AE or dose 
modification) , then report the information as an AE.  
With the exception of laboratory test results that may unblind the study, Lilly or its designee will 
provide the investigator with the results of laboratory tests analyzed by a central vendor, if a  
central vendor is used for the clinical trial.  
8.2.5.  Magnetic Resonance Imaging   
Magnetic resonance imaging of the brain will be performed according to the SoA (Section  1.3) 
and as clinically indicated.  
This technology will be used to check for evidence of clinically relevant exclusion and safety 
findings (vMRI will also be used t o calculate brain volumes, as noted in Section  9.4.3 ). 
The MRI scans will be reviewed by [CONTACT_541450]. Any clinically significant findings noted at baseline that result in a 
diagnosi s should be recorded as a preexisting condition or AE. After the MRI scan is read 
locally, the MRI scans will be sent for analysis to a centralized MRI vendor designated by [CONTACT_11007]. 
Final MRI eligibility at screening will be based on  the centralized MRI read by [CONTACT_55899] , 
which will be reported to the site.   
Specific analyses of the scans, including calculations of brain volumes, will be interpreted by [CONTACT_695457].  
Results of centrally read MRIs r egarding participant  care/safety will be reported back to sites.  
Approved on [ADDRESS_943511] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
61 
 8.2.6.  Hepatic Safety Monitoring   
Close Hepatic Monitoring  
Laboratory tests (Section 10.4), including ALT, AST, ALP, TBL, direct bilirubin, 
gamma -glutamyl transferase, and creatine kinase, should be repeated within 48 to 72 h to 
confi rm the abnormality and to determine if it is increasing or decreasing, if 1 or more of these 
conditions occur:  
If a participant with baseline  results 
of ...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN  
ALP <1.5x ULN  ALP ≥2x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for participant s with Gilbert’s syndrome)  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥2x baseline (except for participant s with Gilbert’s syndrome)  
Abbreviations:  ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
TBL  = total bilirubin level; ULN = upper limit of normal.  
If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation for 
possible causes of abnormal liver tests should be initiated by [CONTACT_61520] -designated Medical Monitor. At a minimum, this eva luation should include physical 
examination and a thorough medical history, including symptoms, recent illnesses ( e.g., heart 
failure, systemic infection, hypotension, or seizures), recent travel, history of concomitant 
medications (including over -the-coun ter), herbal and dietary supplements, and history of alcohol 
drinking and other substance abuse.  
Initially, monitoring of symptoms and hepatic biochemical tests should be done at a frequency of 
1 to 3 times weekly, based on the participant’s clinical cond ition and hepatic biochemical tests. 
Subsequently, the frequency of monitoring may be lowered to once every 1 to 2 weeks, if the 
participant’s clinical condition and laboratory results stabilize. Monitoring of ALT, AST, ALP, 
and TBL should continue until l evels normalize or return to approximate baseline levels.  
Comprehensive Hepatic Evaluation   
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
1 or more of these conditions occur:  
If a participant with baseline  
results of...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN with hepatic signs/symptoms*, or  
ALT or AST ≥5x ULN  
ALP <1.5x ULN  ALP ≥3x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for participant s with Gilbert’s syndrome)  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline with hepatic signs/symptoms*, or 
ALT or AST ≥3x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥1.5x baseline (except for participant s with Gilbert’s syndrome)  
Approved on [ADDRESS_943512] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
62 
 Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
TBL  = total bilirubin level; ULN = upper limit of normal.  
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdom inal pain, fever, rash, 
and/or eosinophilia >5%.  
At a minimum, this evaluation should include physical examination and a thorough medical 
history, as outlined above, as well as tests for Prothrombin time and INR; tests for viral hepatitis 
A, B, C, or E; te sts for autoimmune hepatitis; and an abdominal imaging study ( e.g., ultrasound 
or computed tomography [CT] scan).  
Based on the participant ’s history and initial results, further testing should be considered in 
consultation with the Lilly -designated Medical Monitor, including tests for hepatitis D virus, 
cytomegalovirus, Epstein -Barr virus, acetaminophen levels, acetaminophen protein adducts, 
urine toxicology screen, Wilson’s disease, blood alcohol levels, urinary ethyl glucuronide, and 
serum phosphati dylethanol. Based on the circumstances and the investigator’s assessment of the 
participant’s clinical condition, the investigator should consider referring the participant for a 
hepatologist or gastroenterologist consultation, magnetic resonance cholangio pancreatography, 
endoscopic retrograde cholangiopancreatography, cardiac echocardiogram, or a liver biopsy.   
8.2.7.  Suicidal Ideation and Behavior Risk Monitoring   
Participants  being tr eated with LY3372689  should be monitored appropriately and observed 
closely for suicidal ideation and behavior or any other unusual changes in behavior, especially at 
the beginning and end of the course of intervention , or at the time of dose changes, eith er 
increases or decreases. Consideration should be given to discontinuing the study medication in 
participant s who experience signs of suicidal ideation or behavior, following a risk assessment.   
Families and caregivers of participants  being treated with LY3372689  should be alerted about 
the need to monitor participants  for the emergence of unusual changes in behavior, as well as the 
emergence of suicidal ideation and behavior and to report such symptoms immediately  to the 
study investigator.  
Baseline asses sment of suicidal ideation and behavior/intervention emergent suicidal ideation 
and behavior  will be monitored during Study MTAE  using C-SSRS .   
C-SSRS  
Columbia Suicide -Severity Rating Scale is a scale that captures the occurrence, severity, and 
frequency of suicidal ideation and behavior during the assessment period via a questionnaire. 
The scale was developed by [CONTACT_695458].  
8.3. Adverse Events , Serious Adverse Events , and Product Complaints   
The definitions of the following events can be found in Appendix 3:  
 AEs 
 SAEs  
 PCs 
Approved on [ADDRESS_943513] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
63 
 AEs will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, study partner, 
surrogate, or the participant's legally authorized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE, and remain responsible for following 
up on AEs that are serious, considered related to the IP or study procedures, or that caused the 
participant to discontinue the IP (see Section 7). 
8.3.1.  Timing Period and Frequency for Collecting AE and SAE Information   
All SAEs and AEs will be collected from the signing of the ICF  through the time points specified 
in the SoA (Section  1.3). 
Medical occurrences that begin before the start of IP but after signing of the ICF will be recorded 
on the AE CRF.  
Although all AEs after signing the ICF are recorded by [CONTACT_29558]/electronic data entry, 
SAE reporting to sponsor begins after the participant  has signed the ICF and has received IP or 
PET tracer. However, if an SAE occu rs after signing the ICF, but prior to receiving IP or PET 
tracer , it needs to be reported ONLY if it is considered reasonably possibly related to study 
procedures.  
All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstance should this exceed [ADDRESS_943514] promptly notify the 
sponsor.  
[IP_ADDRESS].  Adverse Event Monitoring with a Systematic Questionnaire   
Nonleading AE collection should occur prior to the collection of the C -SSRS.   
If a su icide -related event is discovered during the C -SSRS but was not captured during the 
nonleading AE collection, sites should not change the AE form.   
If an AE is serious or leads to discontinuation, it needs to be included on the AE form and the 
process for  reporting SAEs is followed.  
8.3.2.  Method of Detecting AEs and SAEs   
The method of recording, evaluating, and assessing causality of AEs and SAEs, and the 
procedures for completing and transmitting SAE reports are provided in Section 10.3. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.  
Approved on [ADDRESS_943515] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
64 
 8.3.3.  Follow -Up of AEs and SAEs   
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs, and AEs of special interest (as defined in Section 8.3.6 ), 
will be followed until resolution, stabilization, the event is otherwise explained, or the participant 
is lost to follow -up (as defined in Section  7.3). Further information on follow -up procedures is 
provided in Section 10.3. 
8.3.4.  Regulatory Reporting Req uirements for SAEs   
Prompt notification by [CONTACT_695459].  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of an IP under clinical investigation. The sponso r will 
comply with country -specific regulatory requirements relating to safety reporting to the 
regulatory authority, IRB/IEC , and investigators.  
An investigator who receives an investigator safety report describing an SAE or other specific 
safety informat ion (e.g., summary or listing of SAEs) from the sponsor will review and then file 
it along with the IB and will notify the IRB/IEC if appropriate according to local requirements.  
8.3.5.  Pregnancy   
Women of childbearing potential are excluded from Study MTAE . Therefore, pregnancy is not 
expected to occur. However, if pregnancy does occur, follow the instructions below.  
Details of all pregnancies in female participants and, if indicated, fe male partners of male 
participants  will be collected after the start of IP and until [ADDRESS_943516] dose of IP 
received.  
If a pregnancy is reported, the investigator should inform the sponsor within 24 h of learning of 
the pregnancy.  
Abnormal pregn ancy outcomes ( e.g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, and ectopic pregnancy) are considered SAEs.  
8.3.6.  Adverse Events of Special Interest   
Specific safety topi[INVESTIGATOR_695421], but are not limited to, the following:  
Approved on [ADDRESS_943517] 2024 GMT
CCI
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943518] so that the situation can be 
assessed.  
8.4. Treatment of Overdose   
In the event of an overdose, the investigator  or treating physician should:  
1. Contact [CONTACT_11008] -designated Medical Mon itor immediately.  
2. Closely monitor the participant for any AE/SAE , laboratory abnormalities , or ECG 
abnormalities .  
3. Obtain a plasma sample for PK analysis of IP if requested by [CONTACT_11008] -designated 
Medical Monitor  (determined on a case -by-case basis)].  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_566804] -designated medical monitor  based on the clinical evaluation of the 
participant.   
8.5. Pharmacokinetics   
At the visits and times specified in the SoA (Section  1.3), venous blo od samples will be collected 
to determine the plasma  concentrations of LY3372689 . A maximum of 3 blood samples per 
participant  may be drawn at additional time points during the study, if warranted and agreed 
upon between both the investigator and sponsor.  The actual date and time (24 -h clock time) of 
each sampl e collected will be recorded . When a blood sample is collected at the time and date of 
last dose , and next to last dose  administration (except at the initial dosing Visit 2), prior to blood  
sampling should be recorded . Instructions for the collection and handling of blood samples will 
be provided by [CONTACT_456] . 
A validated assay will be used to determine plasma L Y3372689  concentrations  from the blood 
samples collected . The blood s amples will be analyzed at a laboratory approved by [CONTACT_456].  
The samples will be retained for a maximum  of [ADDRESS_943519]  study  visit for the study.  
During this time, any sample s remaining  after the bioanalys is is complete may be used for 
exploratory  analyses , such as metabolism, protein binding, or bioanalytical method 
development/validation work.  It is intended that blood samples collected from participant s who 
have received placebo will not be analyzed to measure plasma concentrations of  LY3372689.  
Drug concentration information that may unblind the study will not be reported to investigative 
sites or blinded personnel until the study has been unblinded.  
Approved on [ADDRESS_943520] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
66 
 8.6. Pharmacodynamics   
Biomarker Measures   
8.6.1.  Imaging  Measures   
Flortaucipir F18 PET Scan  
Change in the brain  tau burden (as assessed by [CONTACT_560452] F18 PET) will be compared in 
LY3372689 and placebo -treated participant s for those participants who undergo baseline and 
follow -up flortaucipir F18 scans as described in the SoA (Section  1.3). Flortaucipir F18 PET 
provides quantitative assessment of aggregated tau deposition in the brain and can serve as a PD 
biomarker of accumulation of tau deposits as AD progresses.  
Volumetric MRI  
Assessment of vMRI of the brain will be performed according to the SoA (Section  1.3). 
LY3372689 and placebo -treatment effe cts on MRI will be assessed and compared to evaluate the 
loss of brain volume that occurs in AD participant s. 
8.6.2.  Fluid  Measure s  
Plasm a P-tau will be measured  according to the SoA ( Section 1.3). P-tau levels are associated 
with AD pathology, neurodegeneration , and cognitive worsening  (Janeli dze et al. 2020, 
Matt sson-Carlgren  et al. 2020, Palmqvist 2020 , Thijssen et al. 2020 ). The P-tau immunoassay is 
manufactured by [CONTACT_695460] a central laboratory . When used as a screening test , it is 
an investigational in vitro diagnostic  and will serve to identify parti cipants with increased 
likelihood of having AD tau pathology . It may not be available to all trial sites for screening 
purposes , in which case, screening samples from these sites will only be used for exploratory 
analyses . At study sites utilizing plasma P -tau for screening  purposes , participants that meet P -
tau study eligibility criteria will have  subsequent confirmation of brain tau pathology  by 
[CONTACT_560452] F18 PET.  
[IP_ADDRESS].  Exploratory Biomar kers  
Exploratory biomarker  samples will be collected at timepoints described in the SoA (Section 1.3) 
to  assess  AD pathology, evidence of neurodegeneration  and neuroinflammation , as well as to 
potentially assess additional  novel and developi[INVESTIGATOR_695422], progression , and 
association with study treatment . For example, w ithin the study at baseline and post baseline 
visits, plasma P-tau levels may serve as a disease relevant  PD biomarker.  Additionally , plasma  
neurofilament light chain ( NFL) levels are believed to reflect  neuronal damage  and potentially 
serve as a pharmacodynamic marker for ongoing neurodegen eration  in AD .  Glial fibrillary 
acidic protein (GFAP) is a marker of astroglial injury  associated with neuroinflammatory 
changes in the CNS .  For these reasons, biomarkers may be tested from exploratory samples and 
compared in LY3372689 and placebo -treated participants. These may include but are not limited 
to  P-tau217, NFL,  and GFAP.  
Final testing and analysis plan to be a t sponsor discretion.   
Approved on [ADDRESS_943521] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
67 
 8.7. Genetics   
A blood sample for DNA isolation will be collected from participants  at screening .  
See Appendix 10.7 for information regarding genetic research  and Appendix 10.1.12  for details 
about  sample retention and c ustody .  
8.7.1.  Apolipoprotein E Genotypi[INVESTIGATOR_695423] a mandatory part o f this study, unless country -specific laws and regulations 
prohibit this type of testing. Blood sampling for ApoE genotypi[INVESTIGATOR_695424] ( Section 1.3). Neither participant s nor investigators will receive the genotype results 
unless there is a country -specific law or regulation that requires notification of the results.  
Failure to collect s amples for ApoE will not be considered a protocol deviation if country -
specific regulations prohibit the testing of genetic material or transportation of such material 
outside of the country.  
8.7.2.  Whole Blood Samples for Pharmacogenetic Research   
A whole blood sample will be collected for pharmacogenetic analysis as specified in the SoA 
(Section 1.3) where local regulations allow.  
Samples will not be used to conduct unspecified disease or population genetic research either 
now or in the future. Samples will be used to investigate variable response to LY3372689  and to 
investigate gene tic variants thought to play a role in AD or other neurological conditions. 
Assessment of variable response may include evaluation of AEs or differences in efficacy.  
All samples will be coded with the participant  number. These samples and any data generate d 
can be linked back to the participant  only by [CONTACT_10991].  
Samples will be retained at a facility selected by [CONTACT_134115] a maximum of [ADDRESS_943522] study visit for the study, or for a shorter period if local r egulations and/or 
ERBs/IRBs impose shorter time limits. This retention period enables use of new technologies, 
response to regulatory questions, and investigation of variable response that may not be observed 
until later in the development of LY3372689  or after LY3372689  becomes commercially 
available.  
Molecular technologies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically named. However, existing approaches include whole genome or exome 
sequencing, genome -wide  association studies, and candidate gene studies. Regardless of 
technology utilized, genotypi[INVESTIGATOR_695425].  
8.8. Biomarkers   
Biomarker research is performed to address questions of relevance to drug disposition, target 
engagement, PD, mechanism of action, variability of participant  response (including safety), and 
clinical outcome. Sample collection is incorporated into clinical  studies to enable examination of 
these questions through measurement of biomolecules including deoxyribonucleic acid, RNA, 
proteins, lipi[INVESTIGATOR_805], and other cellular elements.  
Approved on [ADDRESS_943523] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
68 
 8.8.1.  Blood Sample Collection for Exploratory Biomarkers   
Serum, plasma, and whole blood RNA samples for biomarker research will be collected at the 
times specified in the SoA (Section 1.3) where local regulations allow.  Additionally , as indicated 
in Section [IP_ADDRESS] , based on emerging technology , biomarkers may be tested from the exploration 
biomarker samples collected from pa rticipants. These may include  but are not limited to P-
tau217, N FL, and GFAP.  
Samples will be used for research on the drug target, disease process, variable response to 
LY3372689, pathways associated with AD  and other neurodegenerative conditions , mechanism 
of action of LY3372689, and/or research method or in validating diagnostic t ools or assay(s) 
related to AD or other neurodegenerative condition s. 
All samples will be coded with the participant  number. These samples and any data generated 
can be linked back to the participant  only by [CONTACT_10991].  
Samples will be retained at a facility selected by [CONTACT_134115] a maximum of [ADDRESS_943524] of AD on economic issues such as the risk of institutionalization and 
caregiver burden (McLaughlin et al. 2010; Spackman et al. 2013).  
For this purpose , the ADCS -ADL scale will be used to assess changes in dependence levels in 
Study MTAE . The ADCS -ADL scores will be  used to map individuals into 1 of 6 dependence 
levels (0 to 5):   
 Level 0 – no iADL/bADL impairment  
 Level 1 – some supervision needed on isolated iADLs  
 Level 2 – supervision on multiple iADLs or loss of at least 1 household activity  
 Level 3 – supervision on all types of iADLs or homebound  
 Level 4 – supervision on some bADLs , and  
 Level 5 – impaired transfer or complete incontinence (Kahle -Wrobleski et al. 2015).  
An approach to transforming continuous functional scale scores into discrete levels of 
dependence was examined previously in a longitudinal observational study, with preliminary 
results suggesting acceptable validity and progression in dependence level over time (Kahle -
Wrobleski et al. 2017). At baseline, 49.6% of those with mild AD dementia were dependence 
Approved on [ADDRESS_943525] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
69 
 level 2 and 42.7% were at levels 3 or 4. At 18 months, the proportion of participant s at level 2 
declined to 31.2% while that at levels 3 and 4 , rose to 58.8%.  
Analyses will be conducted to examine changes in dependence levels across the t rial population 
as well as potential differences on dependence level by [CONTACT_48977].  
Approved on [ADDRESS_943526] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
70 
 9. Statistical Considerations   
The study population include s early symptomatic AD participant s with evidence of elevated 
pathological tau. The primary efficacy objective of Study MTAE is to demonstrate that 
LY3372689  slow s cognitive and/or functional decline in AD versus placebo as measured by [CONTACT_695461] 76 to  124 weeks in participants with moderate levels of tau pathology at screening . 
Participants with m oderate levels of tau pathology are defined  as those who meet tau PET 
inclusion criteria for evidence of tau  pathology consistent with AD (Fleisher  et al.  2020), but do 
not have  widespread and  high levels of cortical tau  pathology . High levels of cortical tau 
pathology by [CONTACT_695462] a population of amyloid positive Alzheimer’s patients and cognitively normal  
older controls  (Pontecorvo  et al.  2019 ). It is hypothesized that individuals with high tau 
pathology , representing a later pathological stage of disease, where aggregated neurofibrillary 
tau tangles have already spread throughout the brain , may be less likely to benefit from 
LY3372689 . For this reason , the primary objective for this study focus es on a sub-population 
with moderate levels of tau  pathology  as define d by [CONTACT_695463]. The high tau sub -population will 
be included in key secondary analyses. The primary analyses will be conducted by  a DPM , and 
MMRM will be performed  as a sensitivity analysis.  
9.1. Statistical Hypotheses   
The null hypothesis for the primary analysis  is that there is no difference in disease p rogression 
between LY3372689  and placebo  as measured by  [CONTACT_695464]-population . The estimand of the primary analysis is the overall 
treatment effect of LY3372689 vs placebo as measured by  [CONTACT_695465] 124 weeks of study assessments, regardless of 
study treatment discontinuation . 
9.2. Sample Size Determination   
Approximately 330 participant s will be enrolled and randomized in a 1:1:1 ratio to the 3 
treatment arms (placebo and 2 active arms of LY3372689). It is expected that approximately 240 
participant s (i.e. , 75%) will complete the double -blind period 2a 76-week  treatment period of the 
study (approximately 80 per treatment arm). Using a DPM model  over the entire 124 -week 
treatment period , this sample size will provide approximately 96.6% power  
 
 
 
 
 
 
 If the active LY337 2689 treatment arm progressi on 
rate is not different than the placebo  treatment arm  rate, the probability of passing the efficacy 
criterion specified above (i.e., false positive) is approximately 2.4%  
Approved on [ADDRESS_943527] 2024 GMT
CCI
CCI
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
71 
  The simulation for the power calculation and sample size 
determination was carried out in the statistical program R, version  3.6.3.  
9.3. Populations for Analyses   
The f ollowing populations are defined:  
Population  Description  
Entered  All participants who sign the ICF . 
Enrolled/ITT  All participants assigned to treatment, regardless of whether they 
take any doses of study treatment, or if they take the correct 
treatment. Participant s will be analyzed according to the treatment 
group to which they were assigned.  
Efficacy evaluable  For each assessment, the efficacy evaluable population will be 
defined as all participants with a baseline measurement and at least 
[ADDRESS_943528] -baseline measurement for that respective 
assessment. Participants will be grouped according to randomized 
treatment assignment (LY 3372689 or placebo), even if the 
participant does not take the assigned treatment, does not receive 
the correct treatment, or otherwise does not follow the protocol.   
Biomarker evaluable  Same population as efficacy evaluable .  
Safety All participants randomly assigned to IP and who take at least 1 
dose of IP.  
Pharmacokinetic analysis  Same as  safety . 
Abbreviations:  ICF = informed consent form; IP = investigational product.  
9.4. Statistical Analyses   
9.4.1.  General Considerations   
Statistical analysis of this study will be the responsibility of  the Sponsor  or its designee.  
Unless otherwise noted, all pairwise tests of treatment effects will be conducted at a 2 -sided 
alpha level of 0.05 (or equivalently, a 1 -sided 0.025 alpha level); 2 -sided CIs will be displayed 
with a 95% confidence level. All tests of int eractions between treatment and other factors will be 
conducted at an alpha level of 0.05.  
Bretz’s graphical approach may be utilized to provide strong control of the study wise Type I 
error rate for the primary and key secondary hypotheses at an alpha lev el of 0.05 (Bretz et al. 
2009 , 2011). Details on the graphical approach and testing strategy will be specified in the SAP.  
All efficacy analyses will follow the IT T principle unless otherwise specified.  An ITT analysis 
is an analysis of data by [CONTACT_695466] s are assigned by [CONTACT_695467], even 
if the participant  does not take the assigned treatment, does not receive the correct treatment, or 
otherwise does not follow the protocol.  
Approved on [ADDRESS_943529] 2024 GMT
CCI
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943530] had a chance to 
complete their final study visit in the double -blind period of the study  (study period  2a/2b). 
Efficacy and safety analyses will be conducted based on data collected during the double -blind 
period. Data collected during post-treatment safety follow -up period (study period  3) will be 
summarized and analyzed separately.   
Additional database lock (s) may occur  during the post-treatment safety follow -up period  (study 
period 4 ). Efficacy and safety analyses will be conducted based on data collected during the 
double -blind and/or post-treatment safety follow -up period .   
Any change to the data analysis methods described in the protocol will require an amendment 
only if it changes a principal feature of the protocol. Any other change to the data analysis 
methods described in the protocol, and the justification for making th e change, will be described 
in the SAP and the CSR . Additional exploratory analyses of the data will be conducted as 
deemed appropriate.  
The study will include 2 SAPs: a main  study SAP (referred to as Study SAP) which will detail 
the analyses for the objec tives for double -blinded, placebo -controlled phase , and post-treatment 
safety follow -up period ; a supplemental  SAP which will detail the additional exploratory  
analyses  using data collected from post -treatment safety follow -up period .  
The main Study  SAP w ill be finalized prior to unblinding  of all participants in the placebo -
controlled phase , and it will include a more technical and detailed description of the statistical 
analyses described in this section. This section is a summary of the planned statistical analyses of 
the most important endpoints including primary and key secondary endpoint s. 
Handling of missing, unused, and spurious data is addressed prospectively in the overall 
statistical methods described in the protocol and in the SAP s, where appropriate.  
9.4.2.  Primary Endpoint(s)   
Study MTAE has a 76-week  common close design where in all enrolled participants continue on 
study drug and complete study assessments until last enrolled participant  that has not 
discontinued  reach es [ADDRESS_943531] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943532] the hypothesis that LY3372689 slows  cognitive and 
functional decline in early symptomatic AD participants with moderate cortical  tau burden as 
measured by [CONTACT_695468] (76 -124 weeks) . This will 
be assessed using DPM as the primary analysis, and MMRM analysis will be performed as a 
sensi tivity analysis.  
The iADRS  score at each scheduled postbaseline visit (according to the SoA) during the 
treatment period will be the dependent variable. The DPM is as follows:  
𝑌𝑖𝑗=𝛾𝑖+𝑒𝜃𝑇𝑖∑𝛼𝑣𝑗
𝑣=0+𝜀𝑖𝑗,𝑖=1,2,…𝑘;𝑗=1,2,…𝑙 
where 𝑌𝑖𝑗 denote s the clinical outcome at visit j for participant  i, clinical outcome scores at 
baseline (prior to treatment) is 𝑌𝑖0. 𝑇𝑖 denote s the treatment arm for participant i. The parameter  
𝛾𝑖 (i=1, 2, …, k) represent s the subject -specific random effect for participant i. 𝑒𝜃𝑇 is the disease 
progression ratio (D PR) for treatment T and 𝑒𝜃𝑇=1 for placebo ; 𝑒𝜃1 and  𝑒𝜃2 represent the DPR 
of the low dose and the high dose, respectively . The parameter  𝛼𝑣 is the mean change of placebo 
response from visit v-1 to v. 𝜀𝑖𝑗 is the error term. Any stratification variables used for 
randomization such as investigator  site and prior or current use of any approved disease -
modifying therapy for AD will be included in the model.  Baseline  score, baseline age,  
concomitant acetylcholinesterase inhibitor ( AChEI )/memantine use (yes/no)  will be included in 
the model as well. Diffuse priors will be used for the Bayesian inferences in the DPM analys is. A 
DPR  less than 1 correspond s to a slowing of disease progression; similarly, a DPR  greater than [ADDRESS_943533]  (e.g., 0.75 which translates to  25% slowing of disease 
progression with  LY3372689 group versus placebo ). The null hypothesis is that the DPR  
between the LY3372689 group versus placebo equals 1.   
The primary endpoint will also be assessed using natural cubic spline model with degrees of 
freedom 2 (NCS2) and MMRM to serve as sensitivity analys es. Additional  models/analyses may 
be considered if deemed appropriate . The SAP will describe the planned analyses in greater 
detail s. 
9.4.3.  Secondary Endpoint(s)   
The key secondary objective of this study is to test the hypothesis that LY3372689 slows 
cognitive and functional decline in early symptomatic AD participants in the overall population  
as measured by [CONTACT_695469] (76 -124 weeks). It will be 
analyzed using the NCS2, MMRM and the Bayesian DPM  as described in Section 9.4.2 , with t he 
adjustment for tau burden (moderate versus high) as defined by [CONTACT_695470] T.    
Other  secondary efficacy outcomes include ADAS -Cog 13, ADCS -iADL, CDR -SB, and MMSE. 
Each of the se 4 secondary efficacy endpoint s will be assessed using  the same  analysis method(s) 
applied to the prim ary endpoint iADRS and will be analyzed for both moderate tau sub -
population and the overall population.   The change from baseline score at each scheduled 
Approved on [ADDRESS_943534] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
74 
 postbaseline visit (according to the SoA) during the treatment period will be analyzed using the 
NCS2 . Greater details  of model specifications will be provided in the SAP . 
The change from baseline to Week 76 in tau deposition (as measured by [CONTACT_560452] F18 PET 
scan) will be analyzed using an ANCOVA model with terms of baseline value and treatment.   
Longitudinal change in vMRI parameters up to Week 76 will be analyzed using MMRM 
including the following terms in the model: treatment, visit, treatment -by-visit interaction, 
baseline vMRI, and intracranial volume. Other baseline covariate s may be included.  
For data beyond Week 76, including  flortaucipir F18 PET and MRI , MMRM may be used to 
analyze the data with terms of baseline value and treatment.   
An additional analyses of secondary efficacy and biomarkers endpoints may be performed and 
will be pre-specified in the SAP.  
9.4.4.  Tertiary/Exploratory Endpoint(s)   
Exploratory endpoints and their respective analyses will be described in the SAP.  
9.4.5.  Treatment Group Comparability   
[IP_ADDRESS].  Participant Disposition   
All participant s who discontinue from the study will be identified, and the extent of their 
participation in the study will be reported. If known, a reason for their discontinuation  will be 
given.  
The reasons for discontinuation will be collected when the participant ’s participation in the study 
ends and will be summarized by [CONTACT_311579] s.  The percentage 
of participant s discontinuing from each trea tment group will be compared between groups using 
Fisher’s exact test. The comparisons will be done for the overall percentage of participant s who 
discontinue and for select specific reasons for discontinuation.  
[IP_ADDRESS].  Participant Characteristics   
The participant ’s age, sex, race, height, body weight, body mass index (weight (kg)/[height 
(m)]2), tobacco use, alcohol use, caffeine use, years of education, work status, marital status , 
time si nce onset of first AD symptoms, time since diagnosis, baseline MMSE, ApoE genotype 
(e.g., E4 carrier versus non -carrier), having [ADDRESS_943535] degree relatives with AD, and use of 
approved prescription AD medications  will be recorded.  
Baseline characteri stics will be summarized by [CONTACT_1570] , primary efficacy subpopulation , 
and overall  population . Summaries will include descriptive statistics for continuous and 
categorical measures. Fisher’s exact test or Pearson’s chi -square test will be used for treatment -
group comparisons of categorical data. For continuous data, analysis of variance (ANOVA), with 
independent factors for treatment and investigator, will be used.  
[IP_ADDRESS].  Prior and Concomitant Therapy   
Prior medications are defined as those that stop before randomization (Visit 2). Concomitant 
medications are defined as those being taken on or after randomization (Visit 2). A summary of 
Approved on [ADDRESS_943536] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
75 
 concomitant medications will be presented as fr equencies and percentages for each treatment 
group. Fisher’s exact test will be used to test for treatment differences between groups.  
If the start or stop dates of therapi[INVESTIGATOR_695426] r the therapy is prior or concomitant, the therapy will be deemed concomitant.  
Prior and concomitant medications will be listed.  
Summary tables will also be provided for concomitant anticholinergics that affect cognitive 
function and use of approved prescr iption AD medications . 
Medications will be coded using the World Health Organization drug dictionary.  
[IP_ADDRESS].  Treatment Compliance   
The proportion of participants who are significantly nonc ompliant as described in Section 6.4 of 
this protocol will be summarized and compared among all treatment groups using Fisher’s exact 
test.  
9.4.6.  Safety Analyses (s)  
All safety analyses will be made on the Safety Population. Refer to the SAP for additional 
details.  
9.4.7.  Other Analyses   
[IP_ADDRESS].  Pharmacokinetic/Pharmacodynamic Analyses   
LY3372689 plasma concentrations will be illustrated graphically and summarized  descriptively.  
If warranted and based on availability of data, the exposure -response relationship  of LY 3372689  
concentrations to  biomarkers, pharmacodynamic endpoints , efficacy endpoints , and/or  safety 
endpoints may be explored.  Data  from other clinical studies evaluating  LY3372689 may be 
combined with data from this study to support exposure -response analyses. Such  analyses may 
be reported separately . 
[IP_ADDRESS].  Analysis of C -SSRS Data   
Suicide -related thoughts and behaviors occurring during treatment will be summarized based on 
responses to the C -SSRS consistent with the C -SSRS Scoring and Data Analysis Guide 
(CUIMC 2016).  
9.5. Interim Analyses   
Interim  analys es may be conducted for Study MTAE; for example, when 50% of randomized 
participant s have had a chance to complete 52 weeks of treatment (Visit 15) , data may be used to 
evaluate whether to stop the study for futility. Operational details and a quantitative framework 
to provide information for these decisions will be documented in the SAP.  
Only the DMC  is authorized to evaluate unblinded interim efficacy and sa fety analyses. Study 
sites will receive information about interim results only if they need to know for the safety of 
trial participants.  
Approved on [ADDRESS_943537] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943538] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
77 
 10. Supporting Documentation and Operational Considerations   
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Consi derations   
10.1.1.  Regulatory and Ethical Considerations   
● This study will be conducted in accordance with th e protocol and with the 
following:  
o consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines  
o applicable ICH GCP Guidelines ,  
o regulation (EU) No . 536/2014, if applicable, and 
o other applicable laws and regulations . 
● The protocol, protocol amendments, ICF, IB, and other relevant documents ( e.g., 
advertisements) must be submitted to an IRB/IEC by [CONTACT_31846]/IEC  before the study is initiated.  
● Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
● The investigator will be responsible for the following:  
o providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, 
and procedures established by [CONTACT_1201]/IEC  
o notifying the IRB/IEC of SAEs  or other significant safety findings as 
required by [CONTACT_1744]/IEC procedures , 
o providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 C ode of Federal Regulations (C FR), ICH guidelines, 
the IRB/IEC, European regulation 536/2014 for clinical studies (if 
applicable), and all other applicable local regulations . 
o reporting to the sponsor or designee significant issues related to participant safety, 
participan t rights, or data integrity.  
● Investigator sites are compensated for participation in the study  as detailed in the 
CTA . 
10.1.2.  Financial Disclosure   
Investigators and sub -investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
Approved on [ADDRESS_943539] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
78 
 certification or disclosure statements to the appropriate regulatory au thorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
10.1.3.  Informed Consent Process   
● The investigator or his/her representative will explain the nature of the study , 
including the risks and benefits,  to the participant or his/her legally authorized 
representative and answer all  questions regarding the study.  
● Participants must be informed that their participation is voluntary. Participants or 
their legally authorized representative will be required to sign a statement of 
informed consent that meets the requirements of [ADDRESS_943540] 
requirements, where applicable, and the I RB/IEC or study center.  
● The medical record must include a statement that written informed consent was 
obtained before the participant was enter ed in the study and the date  the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.  
● Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study.  
● A copy of the ICF(s) mu st be provided to the participant or the participant’s 
legally authorized representati ve and is kept on file .  
Participants who are rescreened are required to sign a new ICF.  
10.1.4.  Data Protection   
● Participants will be assigned a unique identifier by [CONTACT_695471]’s personal data . Any participant information, such as  records , datasets , 
or tissue samples  that are transferred to the sponsor will contain the ident ifier 
only; participant names or any information which would make the participant 
identi fiable will not be transferred.  
● The participant must be informed that his/her personal study -related data will be 
used by [CONTACT_695472]. The level of 
disclosure must also b e explained to the participant  who will be required to give 
consent for his/her data to be used as described in the informed consent . This is 
done by [CONTACT_695473].  
● The participant must be informed through the informed consent by [CONTACT_695474]/her medical records may be examined by [CONTACT_384303], by 
[CONTACT_6667]/IE C members, and by [CONTACT_6668].  
Approved on [ADDRESS_943541] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
79 
 ● The sponsor has processes in place to ensure information security , data integrity , 
and data protection . These processes address management of data transfer, and 
prevention and management of unauth orized access, disclosure, dissemination, 
alteration or loss of information or personal data . These processes include 
appropriate contingency plan(s) for appropriate and timely response in the event 
of a data security breach.  
 The transfer of personal data is subject to appropriate safeguards through contractual 
agreements and processes. The sponsor’s processes are compliant with local privacy laws 
and relevant legislations including the General Data Protection Regulation (GDPR).  
10.1.5.  Committees Structure   
A DMC consisting of members external to Lilly will be established.  The purpose of the DMC is 
to conduct periodic monitoring of clinical trial data for Study MTAE. The DMC will consist of a 
minimum of [ADDRESS_943542] key efficacy data to put safety observations into context and to 
assess a  reasonable benefit/risk profile for ongoing participant s in the study.  The DMC will 
make recommendation to the Lilly Research Laboratories Senior Management Designee, who 
may order the immediate implementation of the DMC recommendation, or may convene an 
internal review committee, which is independent from the study team, to review the 
recommendation according to standard Lilly policy.  Study sites will receive information ab out 
interim results ONLY if it is required for the safety of their participant s. 
10.1.6.  Dissemination of Clinical Study Data   
Reports  
The sponsor will disclose a summary of study inform ation, including tabular study results, on 
publicly available websites where required by [CONTACT_51967].  
The summary of results will be posted within the time frame specified by [CONTACT_51967]. 
If the study remains ongoing in some countri es and a statistical analysis of an incomplete dataset 
would result in analyses lacking scientific rigor (for example, underpowered) or compromise the 
integrity of the overall analyses (for example, trial not yet unblinded), the summary of results 
will be submitted within [ADDRESS_943543] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943544], see the instructions provided at www. vivli.org. 
10.1.7.  Data Quality Assurance   
● All participant data relating to the study will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically ( e.g., laboratory 
data). The investigator is responsible for verifying that data entries are accurate 
and correct by [CONTACT_1189].  
● The investigator must maintain accurate documentation (source data) that 
supports the informatio n entered in  the CRF.  This includes laboratory tests, 
medical records, and clinical notes.  
● The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct a ccess to source data 
documents . 
 The investigator must review and confirm that data entries are accurate and complete 
throughout the duration of the study, by [CONTACT_1189], as 
instructed by [CONTACT_456]. All completed CRFs must be signed prior to archival.  
● Monitoring details describing strategy ( e.g., risk -based initiatives in operations 
and quality such as risk management and mitigation strategies and analytical risk -
based monitori ng), methods, responsibilities , and requirements, including 
handling of no ncompliance issues and monitoring techniques , are provided in the 
Monitoring Plan.  
● The sponsor or designee is responsible for the data management of this study , 
includin g quality checking of the data.  
● The sponsor assumes accountability for actions dele gated to other individuals 
(e.g., contract research organizations ). 
● The sponsor or designee  will perform monitoring  to confirm that data transcribed  
into the CRF by [CONTACT_1191], complete, and verifiable 
from source documents; t hat the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the currently 
approved protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements.  
Approved on [ADDRESS_943545] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
81 
 ● Records and docum ents, including signed ICFs, pertaining to the conduct of this 
study must be retained by [CONTACT_695475] a longer retention period. 
No records may be destroyed during the retention period without the written 
approval of the sponsor. No records may be transferred to another location or 
party without w ritten notification to the sponsor . 
● In addition, Sponsor  or its representatives will periodically check a sample of the 
participant data recorded against source documents at the study site. The study 
may be audited by [CONTACT_52011], and/ or regulatory agencies at 
any time. Investigators will be given notice before an audit occurs.  
Data Capture System  
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor.  
An (EDC system will be used in this study for the collection of CRF data. The investigator 
maintains a separate source for the data entered by [CONTACT_11002] -provided EDC system.  The investigator is responsible for the identification of any data 
to be considered source and for the confirmation that data reported are accurate and complete by 
[CONTACT_11003] . 
Additionally, COA data ( participant -focused outcome instrument ) will be collected by [CONTACT_236306]/or investigator site personnel , via a paper source document and will be 
transcribed by [CONTACT_126173].  
Additionally, eCOA data ( participant -focused outcome instrument ) will be directly recorded by 
[CONTACT_695476] ( e.g., tablet ).  The eCOA data will serve as the 
source documentation and the investigator does not maintain a separate, written , or electronic 
record of these data.     
Data collected via the sponsor -provided data capture syst em will be  stored at third  party. The 
investigator will have continuous access to the data during the study and until decommissioning 
of the data capture system . Prior to decommissioning, the investigator will receive an archival 
copy of pertinent data for  retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system , and reports  will be provided to the investigator for review 
and retention. Data will subsequently be transfer red from the central vendor to the Sponsor  data 
warehouse.  
Data from complaint forms submitted to Sponsor  will be encoded and stored in the global 
product complaint management system.  
10.1.8.  Source Documents   
● Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
Approved on [ADDRESS_943546] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
82 
 ● Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies 
must be explained. The investigator may need to request previous medical records 
or transfer records, depending on the study. Also, current me dical records must be 
available.  
10.1.9.  Study and Site Start and Closure   
The study start date is the date on which the clinical study will be open for recruitment of 
participants.  
The f irst act of recruitment is the first site open  and will  be the study start date.  
The sponsor designee reserves the right to close the study site or terminate the study at any time 
for any reason at the sole discretion of the sponsor. Study sites will be cl osed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there  is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_11004]  
● Failure of the investigator to comply with the pro tocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines  
● Inadequate recruitment of participants by [CONTACT_093] , and  
● discontinuation of further study intervention development . 
If the study is p rematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_327478]. The investigator shall promptly inform the participant  and assure s 
appropriate participant  therapy and/or follow -up. 
10.1.10.  Publication Policy   
In accordance with the sponsor’s publication policy, the results of this study will be submitted 
for publication by a peer -reviewed journal  if the results are deemed to be of significant medical 
importance .  
10.1.11.  Investigator Informatio n  
Physicians with a specialty in neurology, geriatrics, or psychiatry  will participate as investigators 
in this clinical trial.   In addition, licensed clinicians who have clearly documented  experience in 
AD may participate as investigators in this clinical study.  
10.1.12.  Long -Term Sample Retention   
Sample retention enables use of new technologies, response to regu latory questions, and 
investigation of variable response that may not be observed until later in the development 
of LY3372689  or after  LY3372689  become(s) commercially available.  
Approved on [ADDRESS_943547] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943548] Study  Visit*  
Exploratory biomarkers  Sponsor or Designee  15 years  
PK Sponsor or Designee  2 years  
Genetics  Sponsor or Designee  15 years  
*Retention periods may differ locally.
Approved on [ADDRESS_943549] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
84 
 10.2. Appendix 2: Clinical Laboratory Tests   
 The tests detailed in the table below will be performed by [CONTACT_2237] (unless 
specified otherwise below) . 
 Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 5 of the protocol.  
 Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_357888].  
 Investigators must document their review of each laboratory safety report.  
 Laboratory analyte results denoted below  that could unblind the study will not be 
reported to investigative sites or other blinded personnel.  
Clinical Laboratory Tests   Comments   
Hematology  Assayed by [CONTACT_11007] -designated laboratory  
Hemoglobin    
Hematocrit    
Erythrocyte count (RBCs)    
Mean cell volume    
Mean cell hemoglobin    
Mean cell hemoglobin concentration    
Leukocytes (WBCs)    
Differential    
   Neutrophils, segmented    
   Lymphocytes    
   Monocytes    
   Eosinophils    
   Basophils    
Platelets    
Clinical Chemistry  Assayed by [CONTACT_11007] -designated laboratory  
Sodium    
Potassium    
Total bilirubin    
Direct bilirubin    
ALP    
ALT    
AST    
GGT    
BUN    
Creatinine    
CK   
Uric acid    
Albumin    
Approved on [ADDRESS_943550] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
85 
 Clinical Laboratory Tests   Comments   
Calcium    
Glucose     
Cholesterol    
Hormone Panel  Assayed by [CONTACT_11007] -designated laboratory  
FSH  
LH  
Inhibin B   
Testosterone   
Estrogen   
Urinalysis  Assayed by [CONTACT_11007] -designated laboratory  
Specific gravity    
pH  
Protein   
Glucose   
Ketones   
Blood   
Urine leukocyte esterase   
Biomarkers  Assayed by [CONTACT_11007] -designated laboratory.  Results will not be 
provided to the investigative sites.  
ApoE  Neither participants nor investigators will receive the genotype 
results unless there is a country -specific law or regulation that 
requires notification of the results.  
NFL  
GFAP   
P-tau217   
Hepatic Testing  Assayed by [CONTACT_11007] -designated laboratory    
HBsAg   
Hepatitis C virus RNA PCR   
Genetics sample  Assayed by [CONTACT_11007] -designated laboratory.  Results will not be 
provided to the investigative sites.  
Stored Samples  Assayed by [CONTACT_11007] -designated laboratory.  Results will not be 
provided to the investigative sites.  
Exploratory biomarker samples:    
  PaxGene Tube  for RNA     
  Plasma   
  Serum   
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; ApoE  = apolipoprotein E; AST = 
aspartate aminotransferase; BUN = blood urea nitrogen; CK  = creatine kinase; FSH = follicle -stimulating 
hormone; GFAP = glial fibrillary acidic protei n; GGT = gamma -glutamyl transferase; HBsAg  = hepatitis B 
surface antigen ; IgE  = immunoglobulin  E; LH = l uteinizing hormone ; NFL = neurofilament light chain ; NMH = 
N-methylhistamine; RBC = red blood cell; PK  = pharmacokinetics; P -tau = phosphorylated tau; RNA = 
ribonucleic acid; WBC = white blood cells.  
  
Approved on [ADDRESS_943551] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
86 
 10.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting   
10.3.1.  Definition of AE   
AE Definition  
 An AE is any untoward medical occurrence in a participant administe red a pharmaceutical 
product and  which does not necessarily have a causal relationship with the study 
intervention. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbat ed) temporally 
associated with the use of a medicinal (investigational) product, whether or not related to 
the medicinal (investigational) product.  
 
Events Meeting  the AE Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (e.g., ECG, radiological scans, or vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the investigator (i.e ., not related to progression of underlying 
disease).  
 Exacerbation of a chronic or intermittent preexisting condition, including either an increase 
in frequency and/or intensity of the condition.  
 New condition(s) detected or diagnosed after IP administrati on, even though it may have 
been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Medication error, misuse, or abuse of IMP, including signs, symptoms, or clinical 
sequelae.  
 “Lack of eff icacy” or “failure of expected pharmacological action” per se will not be 
reported as an AE/SAE.  Such instances will be captured in the efficacy assessments.  
However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will 
be reported as an AE/SAE if they fulfill the definition of an AE/SAE.  
 
Approved on [ADDRESS_943552] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
87 
 Events NOT  Meeting the AE Definition  
 Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by [CONTACT_11009]’s condition.  
 The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for th e participant’s 
condition.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
 Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
10.3.2.  Definition of SAE   
If an event is not an AE per definition above, then it cannot be an SAE, even if serious 
conditions are met (e.g., hospi [INVESTIGATOR_1080]/symptoms of the disease under study, death due 
to progression of disease).  
An SAE is defined as any untoward medical occurrence that at any dose:  
a. Results in death  
b. Is life -threatening  
The term “life-threatening ” in the definition of “serious ” refers to an event in which the 
participant was at risk of death at the time of the event.  It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.  
c. Requires in  participant  hospit alization or prolongation of existing hospi[INVESTIGATOR_059]  
 In general, hospi[INVESTIGATOR_695427]/or treatment that would not have been appropriate in the 
physician’s office or out  participant  setting.  Complications that occur during 
hospi[INVESTIGATOR_1084].  If a complication prolongs hospi[INVESTIGATOR_13270], the event is serious.  When in doubt as to whether “hospi[INVESTIGATOR_059]” 
occurred or was necessar y, the AE should be considered serious.  
 Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.  
d. Results in persistent disability/incapacity  
 The term disability means a substantial disrup tion of a person’s ability to conduct 
normal life functions.  
 This definition is not intended to include experiences of relatively minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (e.g. , sprained ankle), which may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.  
Approved on [ADDRESS_943553] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
88 
 e. Is a congenital anomaly/birth defect  
Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenita l 
anomalies, and ectopic pregnancy) are considered SAEs.  
f. Other situations:  
 Medical or scientific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_228057] t he 
participant or may require medical or surgical intervention to prevent one of the other 
outcomes listed in the above definition.  These events should usually be considered 
serious.  
 Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or 
drug abuse.  
g. Resulted in medical or surgical intervention to prevent life-threatening illness or injury or 
permanent impairment to a body structure or a body function.  
10.3.3.  Definition of Product Complaints   
Product Complaint  
 A product complaint is any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness , or 
performance of a study intervention . When the ability to use the study intervention s afely 
is impacted, the following are also product complaints:  
o Deficiencies in labeling information . 
 Product complaints related to study interventions used in clinical trials are collected in 
order to ensure the safety of participants, monitor quality, and to facilitate process and 
product improvements.  
 Investigators will instruct participants to contact [CONTACT_543100] 
a product complaint or problem with the study intervention so that the situation can be 
assessed.  
 An event may  meet the definition of both a product complaint and an AE/SAE. In such 
cases, it should be reported as both a product complaint and as an AE/SAE.  
 Device deficiencies are product complaints.  
10.3.4.  Recording and Follow -Up of AE and/or SAE  and Product Complaints   
AE, SAE , and Product Complaint Recordin g 
 When an AE/SAE /product complaint occurs, it is the responsibility of the investigator to 
review all documentation ( e.g., hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics 
reports) related to the event.  
Approved on [ADDRESS_943554] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
89 
  The investigator will then record all relevant AE/ SAE/product complaint information in 
the participant’s medical records, in accordance with the investigator’s normal clinical 
practice. AE/SAE information is reported on the appropriate (e)CRF page , and product 
complaint information is reported on the Product Complaint Form.  
Note: An event may meet the definition of both a product complaint and an AE/SAE. In such 
cases, it should be reported as both a product complaint and as an AE/SAE.  
 It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to Sponsor or designee in lieu of completion of t he (e)CRF page for AE/SAE and 
the Product Complaint Form for product complaints.  
 There may be instances when copi[INVESTIGATOR_695428]. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_51959].  
 The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Wheneve r possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to 1 of the following categories:   
 Mild: A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual activities of 
daily living.  
 Moderate: A type of AE that is usually all eviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, causing discomfort 
but poses no significant or permanent risk of harm to the research participant.  
 Severe: A type of AE that interrupts u sual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention. An AE that is assessed as 
severe should not be confused with a SAE. Severe is a category utilized for rating the 
intensity of an e vent; and both AEs and SAEs can be assessed as severe.  
An event is defined as “serious ” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.   
Assessment of Causality  
 The investigator is obligated to assess the relationship between IP and each occurrence of 
each AE/SAE.  
 A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relati onship cannot be ruled out.  
 The investigator will use clinical judgment to determine the relationship.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to IP a dministration will be 
considered and investigated.  
Approved on [ADDRESS_943555] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
90 
  The investigator will also consult the IB and/or Product Information, for marketed 
products, in his/her assessment.  
 For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
 There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the sponsor or designee.  However, it is very 
important that the investigator always make an assessment of causality for every event 
before the initial transmission of the SAE data to the sponsor or designee.  
 The investigator may change his/her opi[INVESTIGATOR_9242] -up information 
and send an SAE f ollow -up report with the updated causality assessment.  
 The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
 
Follow -Up of AEs and SAEs  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_41443]/or causality of the AE or SAE as fully as possible.  
This may include additional laboratory tests or inves tigations, histopathological 
examinations, or consultation with other health care professionals.  
 If a participant dies during participation in the study or during a recognized follow -up 
period, the investigator will provide the sponsor or designee with a c opy of any 
postmortem findings, including histopathology.  
10.3.5.  Reporting of SAEs   
SAE Reporting via an Electronic Data Collection Tool  
 The primary mechanism for reporting an SAE will be the electronic data collection tool.  
 If the electronic system is unavailable, then the site will use the paper SAE data collection 
tool (see next section) in order to report the event within 24 h.  
 The site will enter the SAE data into the electroni c system as soon as it becomes available.  
 After the study is completed at a given site, the electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data.  
 If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electronic data collection tool has been taken off -
line, then the site can report this information on a paper SAE form (see ne xt section) or to 
the Lilly -designated medical monitor  by [CONTACT_756].  
 SAE reporting is done through the eCRF.  
 
Approved on [ADDRESS_943556] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
91 
 SAE Reporting via Pap er CRF  
 Facsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to the Lilly -designated Medical Monitor . 
 In rare circumstances and in the absence of facsimile equipment, notification by [CONTACT_13186] a copy o f the SAE data collection tool sent by [CONTACT_13187].  
 Initial notification via telephone does not replace the need for the investigator to complete 
and sign the SAE CRF pages within the designated reporting time frames.  
 Contacts for SAE  reporting can be found on the paper CRF.  
10.3.6.  Regulatory Reporting Requirements   
SAE Regulatory Reporting  
Prompt notification by [CONTACT_11012] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a 
study intervention under clinical investigation are met.  
● The sponsor has a legal responsibility to notify both the local regulatory au thority and 
other regulatory agencies about the safety of a study intervention under clinical 
investigation. The sponsor  will evaluate the reported SAEs, including confirmation of 
relatedness and assessment of expectedness. The sponsor has processes for sa fety reports 
for identification, recording, and expedited reporting of S[LOCATION_003]Rs according to local 
regulatory requirements. The sponsor will comply with country -specific regulatory 
requirements relating to safety reporting to the regulatory authority, IRB/  IEC, and 
investigators.  
● An investigator who receives an investigator safety report describing a SAE or other 
specific safety information (e.g., summary or listing of SAEs) from the sponsor will review 
and then file it along with the IB and will notify the IRB/IEC, if appropriate according to 
local requirements.  
EU-specific r egulatory reporting requirements  
The sponsor has processes for safety reports for identification, recording, and expedited 
reporting of S[LOCATION_003]Rs  according to  EU regulatory requirements.  The sponsor will comply wi th 
applicable  regulatory requirements relating to safety reporting to the regulatory authority , per 
European Union Clinical Trial Regulation 536/[ADDRESS_943557] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
92 
 10.4. Appendix 4:  Liver Safety:  Suggested Actions and Follow -Up 
Assessments   
Selected tests may be obtained in the event of a treatment -emergent hepatic abnormality and may 
be required in follow -up with participant s in co nsultation with the Lilly, or its designee,  CRP . 
Hepatic Evaluation Testing  
See Section 8.2.[ADDRESS_943558] bilirubin  
Erythrocytes (RBCs)  ALP  
Leukocytes (WBCs)  ALT  
Differential:  AST  
    Neutrophils, segmented  GGT  
    Lymphocytes  CK 
    Monocytes  Other Chemistry  
    Basophils  Acetaminophen  
    Eosinophils  Acetaminophen protein adducts  
Platelets  Alkaline phosphatase isoenzymes  
Cell morphology (RBC and WBC)  Ceruloplasmin  
Coagulation  Copper  
EtOH  
Prothrombin time, INR (PT -INR)  Haptoglobin  
Serology  Immunoglobulin IgA (quantitative)  
 HAV testing:  Immunoglobulin IgG (quantitative)  
    HAV total antibody  Immunoglobulin IgM (quantitative)  
    HAV IgM antibody  PEth  
HBV testing:  Urine Chemistry  
HBsAg  Drug screen  
    anti-HBs EtG 
    anti-HBc Other Serology  
Approved on [ADDRESS_943559] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
93 
     Hepatitis B core IgM antibody  ANA  
    Hepatitis B core IgG antibody  ASMA a 
    HBV DNA d Anti-actin antibody b 
HCV testing:  EBV testing:  
    HCV antibody      EBV antibody  
    HCV RNA d     EBV DNA d 
HDV testing:   CMV  testing:  
    HDV antibody      CMV antibody  
HEV testing:      CMV DNA d 
    HEV IgG antibody  HSV testing:  
    HEV IgM antibody      HSV (Type 1 and 2) antibody  
    HEV RNA d     HSV (Type 1 and 2) DNA  d 
Microbiology c LKM -1 antibody  
Culture:   
    Blood   
    Urine   
Abbreviations:  ALP = alkaline phosphatase; ALT = alanine aminotransferase ; ANA = anti -nuclear antibody; 
anti-HBc =  hepatitis B core total antibody ; anti -HBs = hepatitis B surface antibody ; 
ASMA  = anti-smooth  muscle antibody; AST = aspartate aminotransferase ; CK = creatine kinase;  
CMV  = cytomegalovirus; EBV  = Epstein -Barr virus; EtG = ethyl glucuronide; EtOH = ethyl alcohol ; 
GGT  = gamma -glutamyl  transferase ; HAV = hepatitis A virus; HBsAg = hepatitis B surface antigen; 
HBV = hepatitis B virus; HCV = hepatitis C virus; HDV = hepatitis D virus; HEV = hepatitis E virus; 
HSV  = herpes simplex virus; LKM -1 = liver kidney microsomal type 1 , Peth  = phosphatidylethanol;  
RBC  = red blood cell; WBC = white blood cell  
Footnotes: 
a Not required if anti -actin antibody is tested.  
b Not required if anti -smooth muscle antibody (ASMA) is tested.  
c Assayed ONLY by [CONTACT_1697] -designated local laboratory; no central testing available.  
d Reflex/confirmation dependent on regulatory requirements, testing availability, or both.  
  
Approved on [ADDRESS_943560] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
94 
 10.5. Appendix 5:  Flortaucipir F18 Tau PET Imaging   
Flortaucipir F18 PET scans will be performed as part of the study eligibility criteria and as 
indicated in the SoA (Section  1.3). 
For inclusion and exclusion criteria related to the flortaucipir F18 PET scans, refer to 
Sections   5.[ADDRESS_943561] state -of-the-art imaging systems are designed to re duce head motion 
and participant  discomfort.  
The table below shows the effective radiation dose of the Study MTAE ’s PET scans.  
 Effective Dose 
(mSv) per 
Scana,b Number of 
Scans in First 
Year  Effective Dose 
(mSv) for 
Scans in First 
Year  Number of 
Scans in 
Second Yeara Effective Dose 
(mSv) for 
Scans in 
Second Year  Sum of 
Effective Dose 
(mSv) for 
Years 1 and 2  
Flortaucipir 
F18 Scan (10 
mCi IV)  9.10 1 9.10 2 18.20 27.30 
Abbreviations:   IV = intravenous infusion; PET  = positron emission tomography.  
a All participant will receive at least one scan in second year, a second scan in Year [ADDRESS_943562] scan is obtained 
(estimated at 0.4 mSv) as part of the PET scan attenuation correction process when the scan is done on a PET/CT 
scanner.  A clinical CT scan is not needed during the PET scan session and, because it will add additional radiation 
exposure, it is not recomme nded.   
Note:  In the event a repeat scan is required ( e.g., the scan is not analyzable), [ADDRESS_943563] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
95 
 10.6. Appendix 6: Contraceptive Guidance and Collection of Pregnancy 
Information   
Please see Section 5.1 for details  on contrace ptive guidance.   
Collection of Pregnancy Information  
Male participants wi th partners who become pregnant  
● The investigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this stu dy. This applies 
only to male participants who receive study intervention . 
● After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the investigator will record pregnancy information on the appropriate form and 
submit it to the sponsor within 24 h of learning of the partner’s pregnancy. The female 
partner will also be followed to determine the outcome of the pregnancy. Information on the 
status of the mother and child will be forwarded to the sponsor. Generally, the  follow -up will 
be no longer than 6 to 8  weeks following the estimated delivery date. Any termination of the 
pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or 
indication for the procedure.  
Female Participants who b ecome pregnant  
Women of childbearing potential are excluded from Study MTAE. Therefore, pregnancy is not 
expected to occur. However, if a female participant becomes pregnant:   
● The investigator will collect pregnancy information on any female participant who becomes 
pregnant while participating in this study.  The initial information will be recorded on the 
appropriate form and submitted to the sponsor within 24 h of learning of a participant's 
pregnancy.  
● The participant will be followed to determine the outcome of the pregnancy. The investigator 
will collect follow -up information on the participant , and the neonate and the information 
will be forwarded to the sponsor. Generall y, follow -up will not be required for longer than 6 
to 8 weeks beyond the estimated delivery date. Any termination of pregnancy will be 
reported , regardless of fetal status (presence or absence of anomalies) or indication for the 
procedure.  
● While pregnan cy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
● A spontaneous abortion (occurring at <2 0 weeks gestational age) or still birth (occur ring at 
>20 weeks gestational age) is always considered to be an SAE and will be reported as such.  
● Any post -study pregnancy -related SAE considered reasonably related to the study 
intervention by [CONTACT_51995]  8.3.4 . While the investigator is not obligated to actively seek this information in 
former study participants, he or she may learn of an SAE through spontaneous reporting.  
● Any female participant who becomes pregnant while participating in the study  will be 
withdrawn from the study .  
Approved on [ADDRESS_943564] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
96 
 10.7. Appendix  7: Genetics   
Use/Analysis of DNA  
● Genetic variation may  impact a participant’s response to study intervention, susceptibility to, 
and severity and progression of disease. Variable response to study intervention may be due 
to genetic determinants that impact drug absorption, distribution, metabolism, and excret ion; 
mechanism of action of the drug; disease etiology; and/or molecular subtype of the disease 
being treated. Therefore, where local regulations and IRB/IEC allow, a blood/saliva  sample 
will be collected for DNA analysis from consenting participants.  
● DNA samples will be used for research related to study intervention  or indication  and related 
diseases. They may also be used to develop tests/assays including diagnostic tests related to  
study intervention and/or interventions of this drug class  and indication . Genetic research 
may consist of the analysis of one or more candidate genes or the analysis of genetic markers 
throughout the genome or analysis of the entire genome  (as appropriate).  
● DNA samples will be analyzed for planned analyses . Additio nal analyses may be conducted 
if it is hypothesized that this may help further understand the clinical data.  
● The samples may be analyzed as part of a multi -study assessment of genetic factors involved 
in the response to study intervention  or study interv entions of this class to understand study 
disease or related conditions.  
● The results of genetic analyses may be reported in the CSR or in a separate study summary.  
● The sponsor will store the DNA samples in a secure storage space with adequate measures to 
protect confidentiality.  
● The samples will be retained while research on study intervention or study interventions of 
this class or indication  continues but no longer than [ADDRESS_943565] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943566] planned study procedures.  
Implementing Changes under Exceptional Circumstances  
In an exceptional circumstance, after receiving the sponsor’s written approval, sites may 
implement changes if permitted by [CONTACT_427].  
After approval by [CONTACT_31086], regulatory bodies , and any other relevant local 
authorities, implementation of thes e exceptional circumstance changes will not typi[INVESTIGATOR_51960], unless they have specific conditions in which notification 
is required. To protect the safety of study participants, urgent changes may be implemented 
before approval but need to be reported as soon as possible. All approvals must be retained in the 
study records.  
If the sponsor grants written approval for changes in study conduct, the sponsor will also provide 
additional written guidance, if needed.  
Consi derations for Making a Change  
The prevailing consideration for making a change is ensuring the safety of study participants. 
Additional important considerations for making a change are compliance with GCP, enabling 
participants to continue safely in the study and maintaining the integr ity of the study.  
Informed Consent  
Additional consent from the participant will be obtained, if required, for:  
 participation in remote visits, as defined in Section “Remote Visits”  
 dispensation of additional study intervention during an extended treatment  period  
 alternate delivery of study intervention and ancillary supplies, and  
 provision of their personal or medical information required prior to implementation of 
these activities.  
Changes in Study Conduct during Exceptional Circumstances  
Changes in stu dy conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed.  
Approved on [ADDRESS_943567] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943568] complaints remain unchang ed. Furthermore, every effort 
should be made to enable participants to return to on -site visits as soon as reasonably possible, 
while ensuring the safety of both the participants and the site staff.  
Telemedicine: Telephone or technology -assisted virtual vi sits, or both, are acceptable to 
complete appropriate assessments. Assessments to be completed in this manner may include the 
assessments below.   
Clinician -Administered Assessments (Electronic)  
 ADAS -Cog 13 
 ADCS -ADL  
 CDR  
 MMSE  
 DSST , and  
 Digital Clock . 
Clinician -Administered Assessment (Paper)  
 C-SSRS baseline  
 C-SSRS Since Last Visit  
Mobile healthcare:  Healthcare visits may be performed by a mobile healthcare provider at 
locations other than the study site when participants cannot travel to the site due to an 
exceptional circumstance if written approval is provided by [CONTACT_456] . Procedures performed at 
such visits include, but are not limited to,  
 Physical Evaluation  
 Laboratory Tests , and  
 Sample Collections .  
Other alternative locations:   Procedures that may be done at an alternate location , other than  
listed above  include  
 Physical Evaluation  
 Laboratory Tests , and   
 Sample Collections .  
Local Laboratory Testing Option  
Local laboratory testing may be conducted in lieu of some central laborator y testing.   
Approved on [ADDRESS_943569] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
99 
  Obtain local  labs for safety (hematology, chemistry , hormone panel, and urinalysis ) 
when applicable, as per the SoA.   
 All labs will be reviewed by [CONTACT_473]. Lilly Medical should be informed of 
any labs that meet criteria for temporary or permanent study drug discontinuation.    
 Sign and date review of local labs per normal process and follow -up with the 
participant  as needed.  Results will not be recorded in the eCRF.    
 Safety labs should be obtained as specified in the SoA. 
The local laboratory must be qualified in accordance with applicable local regulations.  
Study Intervention and Ancillary Supplies  
When a  participant is unable to go to the site to receive study supplies during normal on -site 
visits, the site should work with the sponsor to determine appropriate actions.  These actions may 
include   
 asking the participant to go to the site and receive study supplies from site staff 
without completion of a full study visit  
 asking the participant’s designee to go to the site and receive study supplies on a 
participant’s behalf, and 
 arranging delivery of study supplies . 
These requirements must be met before action is taken:  
 Alternate delivery of IP should be performed in a manner that does not compromise 
treatment blinding and ensures product integrity. The existing protocol requirements 
for product accountability remain unchanged, including verificati on of participant’s 
receipt of study supplies.  
 When delivering supplies to a location other than the study site ( e.g., participant’s 
home), the investigator, sponsor, or both should ensure oversight of the shippi[INVESTIGATOR_695429] ( i.e., storage conditions 
maintained and intact packaging upon receipt).  
 Instructions may be provided to the participant or designee on the final disposition of 
any unused or completed study supplies . 
Screening Period Guidance  
To ensure safety  of study participants, laboratory values and other eligibility assessments taken 
at screening visit  are valid for a maximum of [ADDRESS_943570] be pau sed due to 
exceptional circumstances:  
 If paused for less than [ADDRESS_943571] the next visit if the participant’s eligibility criteria are 
confirmed, and the site should document the reason for delay.  
Approved on [ADDRESS_943572] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
100 
 o Due to the pause in screening, sites should also reconfirm the impacted 
participant’s consent and document this confir mation in the source 
documentation.  
 If paused for more than 90 days from screening : the participant must be discontinued 
because of screening interruption due to an exceptional circumstance.   This is 
documented as a screen fail ure in the CRF.   This screen fail is allowed in addition to 
the main protocol screen fail. The participant can reconsent and be rescreened as a 
new participant. The screening procedures per the usual SoA should be followed, 
starting at screening visit to ensu re participant eligibility by [CONTACT_170283].  
Adjustments to Visit Windows  
Whenever possible and safe to do so, as determined by [CONTACT_093]’s discretion, participants 
should complete the usual SoA. To maximize the possibility that these visits can be conducted as 
on-site visits, the windows for visits may be adjusted, upon further guidance from the sponsor. 
This minimizes missing data and preserves the intended conduct of the study.  
This table describes the allowed adjustments to visit windows.  
Visit Number  Tolerance  
For Study 
Period s 2a 
and 2b  ±[ADDRESS_943573] will be documented : 
 Sites will identify and document the details of how participants, visit types, and 
conducted activities were affected by [CONTACT_52022]. 
Dispensing/shipment records of study intervention and relevant communications, 
including delegation, shoul d be filed with site study records.  
 Source documents generated at a location other than the study site should be part of 
the investigator’s source documentation and should be transferred to the site in a 
secure and timely manner.  
  
Approved on [ADDRESS_943574] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
101 
 10.9. Appendix 9: Abbreviations   
Term  Definition  
abuse  Use of a study intervention for recreational purposes or to maintain an addiction or 
dependence  
ADAS -Cog 13 Alzheimer’s Disease Assessment Sc ale - Cognitive subscale  
ADCS -ADL  Alzheimer’s Disease Cooperative Study - Activities of Daily Living Inventory  
ADCS -iADL  Alzheimer’s Disease Cooperative Study - instrumental Activities of Daily Living  
AE adverse event  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
ANCOVA  analysis of covariance  
ApoE  apolipoprotein E  
AST  aspartate aminotransferase  
authorized IMP  Applicable to the EU only : a medicinal product authorized in accordance with 
Regulation (EC) No 726/2004  or in any Member State concerned in accordance with 
Directive 2001/83/EC, irrespective of changes to the labelling of the medicinal product, 
which is used as an investigational medicinal product  
bADLs  basic Activities of Daily Living  
blinding/masking  a single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the participant is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the participa nt are not.  
A double -blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the 
participants are aware of the treatment received.  
MMRM  Mixed model for repeated measures  
CDR -SB Clinical Dementia Rating Scale - Sum of Boxes  
CIOMS  Council  for International  Organizations  of Medical  Sciences  
CNS  central nervous system  
COA  clinical outcome assessment  
complaint  a complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.  
compliance  adherence to all study -related, good clini cal practice (GCP), and applicable regulatory 
requirements.  
Approved on [ADDRESS_943575] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
102 
 Term  Definition  
CRP  clinical research physician:  individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician,  clinical research 
scientist, global sa fety physician or other medical officer.  
CSR  clinical study report  
CTA  clinical trial agreement  
DART  Developmental and Reproductive Toxicology  
DMC  Data Monitoring Committee  
DPM  disease progression model  
ECG  electrocardiogram  
eCOA  electronic Clinical Outcome Assessment  
EDC  electronic data capture  
enroll  the act of assigning a participant to a treatment.  Participants who are enrolled in the 
study are those who have been assigned to a treatment.  
enter  participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.  
EO enzyme occupancy  
GCP  good clinical practice  
HBsAg  Hepatitis B surface antigen  
iADRS  integrated Alzheimer’s Disease Rating Scale  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICE Independent Ethics Committees  
ICH  International Council for Harmonisation  
INR international normalized ratio  
IMP  Investigational Medicinal Product  (see also “ investigational product ”) 
A medicinal product which is being tested or used as a reference, including as a 
placebo, in a clinical trial.  
Approved on [ADDRESS_943576] 2024 GMT
CCI
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
103 
 Term  Definition  
Informed consent  a process by [CONTACT_9444] a participant voluntarily confirms his or her willingness to 
participa te in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate.  Informed consent is 
documented by [CONTACT_3553] a written, signed and dated informed consent form . 
interim analysi s an interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.  
investigational product  a pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or mark eted products used to 
gain further information about the authorized form.  See also “IMP.”  
IP investigational product  
IRB Institutional Review Boards  
ITT intention to treat: the principle that asserts that the effect of a treatment policy can be 
best assessed by [CONTACT_41445] a participant (that is, the 
planned treatment regimen) rather than the actual treatment given.  It has the 
consequence that participant allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.  
IWRS  interactive web -response system  
MAD  multiple ascending dose  
medication error  Errors in the prescribing, dispensing, or administration o f a study intervention, 
regardless of whether or not the medication is administered to the participant or the 
error leads to an AE. Medication error generally involve a failure to uphold one or more 
of the five “rights” of medication use: the right partici pant, the right drug, the right 
dose, right route, at the right time.  
In addition to the core five rights, the following may also represent medication errors:  
• dose omission associated with an AE or a product complaint  
• dispensing or use of expi[INVESTIGATOR_51963]  
• use of medication past the recommended in -use date  
• dispensing or use of an improperly stored medication  
• use of an adulterated dosage form or administration technique inconsistent with the 
medication's labeling (for example, Summary  of Product Characteristics, IB, local 
label, protocol), or  
• shared use of cartridges, prefilled pens, or both.  
misuse  Use of a study intervention for self -treatment that either is inconsistent with the 
prescribed dosing regimen, indication, or both, or is obtained without a prescription  
MMSE  Mini Mental State Examination  
Approved on [ADDRESS_943577] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943578] level  
OGA  O-linked N -acetyl glucosaminidase  
O-GlcNAc  O-linked β-N-acetyl glucosamine  
OLE  open -label extension  
participant  equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_10930] a control  
PC product complaint  
PET  Positron emission tomography  
PK/PD  pharmacokinetics/pharmacodynamics  
PPS per-protocol set:  The set of data generated by [CONTACT_695477] s of treatment, according to the underlying scientific model.  
PRO/ePRO  participant -reported outcomes/electronic participant -reported outcomes  
QD once daily  
QTc  corrected QT interval  
SAC  statistical analysis center  
SAD  single ascending dose  
SAE  serious adverse event  
SAP  statistical analysis plan  
screen  the act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study.  
SoA schedule of activities  
S[LOCATION_003]Rs  suspected unexpected serious adverse reactions  
Refers to an adve rse event that occurs in a clinical trial participant, which is assessed by 
[CONTACT_695478], serious and as having a 
reasonable possibility of a causal relationship with the study intervention.  
TBL  total bilirubin  level  
Approved on [ADDRESS_943579] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
[ADDRESS_943580] -party organization  
TEAE  treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.  
ULN  upper limit of normal  
vMRI  volumetric magnetic resonance imaging  
  
Approved on [ADDRESS_943581] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
106 
 10.10.  Appendix 10: Protocol Amendment History   
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).  
Amendment [d] (18 -Apr-2024)  
This amendment is considered to be nonsubstantial.  
Overall Rationale for the Amendment  
The mai n rationale for this amendment is to make corrections as specified in the table below.  
Section # and Name  [CONTACT_11029]  
6.1 Study 
Intervention(s) 
Administered  Deleted sentence about supplying 
blister packaging.  To provide flexibility in the packaging to be 
used.  
6.3 Measures to 
Minimize Bias: 
Randomization and 
Blinding  Deleted sentence about supplying 
blister packaging.  To provide flexibility in the packaging to be 
used.  
7.[ADDRESS_943582] to follow -up. To provide flexibility in operations.  
Amendment [c] (22-Mar -2024 ) 
This amendment is considered to be substantial.  
The amendment is considered to be substantial because it is likely to have a significant impact on 
the 
● safety or the rights of the study participants,  and 
● reliability and robustness of the data generated in the clinical study . 
Overall Rationale for the Amendment:  
The main rationale of this amendment is to  update the study design with the addition of an 
optional open -label extension period and an optional substudy for flortaucipir F18 PET imaging 
and MRI scans to assess long term safety and extended biomarker.   
Section # and Name  [CONTACT_695484]:  
flortaucipir F18 PET  For consistency and clarity  
Title Page  Regulatory Agency Identifier 
Number(s):  
Added EU CT number  Compliance with EU -CTR  
Added subsections : 
Approved on [ADDRESS_943583] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
107 
 Section # and Name  [CONTACT_11029]  
1.1. Synopsis   Regulatory Agency Identifier 
Numbers (IND, EudraCT , and EU 
CT number)  
 Study Population  
 Ethical Considerations of 
Benefit/Risk  
Deleted language from Rationale  For conciseness  
Objectives and Endpoints subsection:  
Deleted exploratory objectives and 
endpoint  
Added table and corresponding 
abbreviations depi[INVESTIGATOR_695430] -label 
extension (OLE) period   
For conciseness  
 
To reflect the changes in the modified open -
label study design  
Overall desi gn subsection:  
Updated the overall  design as per the 
modified study design  and deleted the 
disclosure statement . 
Intervention Groups and Duration 
subsection:  
 Modified total study duration 
from “137 weeks ” to “217 
weeks ” 
 Added duration and follow -up 
for the OLE period  
1.2. Schema  New figure and corresponding 
footnote have been added for the 
OLE period  To reflect the changes in the modified open -
label study design  
1.3. Schedule of 
Activities (SoA)  
1.3.1. Study Period 2a - 
Treatment Period  
1.3.2. Study Period 2b - 
Treatment Period  Added table headings  Clarification  
1.3.1. Study Period 2a - 
Treatment Period  Laboratory tests and sample 
collection row:  
Added hormone panel testing 
(testosterone, LH, FSH, Inhibin B) at 
Visit 21   
 Added footnote ‘c’ detailing 
specifics for ET MRI scan  
 Updated footnote ‘h’ with 
specifics for hormone panel 
collection  Clarification  
Approved on [ADDRESS_943584] 2024 GMT
CCI
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
108 
 Section # and Name  [CONTACT_11029]  
1.3.2. Study Period 2b - 
Treatment Period  Laboratory tests and sample 
collection row:  
 Added hormone panel testing 
(testosterone, LH, FSH, Inhibin 
B) at Visit 23, 25, 27, 29, ET, 
V801 and added applicable 
comments  
 Added footnote ‘d’ and ‘i’ 
detailing specifics for ET MRI 
scan and hormone panel 
collection   
1.3.3. Study Period 4 -
Open -Label Extension 
Period (newly added 
section)  Added study activities and 
procedures to be performed in  the 
OLE period. Also, added 
corresponding footnote  To reflect the changes in the modified open -
label study design  
3. Objectives and 
Endpoints  Added objectives and endpoints to be 
evaluated in the OLE period  
4.1. Overall Design   Modified total study duration  
 Added duration and follow -up 
for the OLE period  
 Added criteria for participants 
who will be offered to enter 
OLE Study MTAE  
4.1.5. Optional 
Extension Period (newly 
added section)  Added eligibility criteria, dosing, and 
follow -up duration for the OLE 
period  
4.2. Scientific Rationale 
for Study Design  Added paragraph on  rationale for the 
modified study design  
4.3. Justification for 
Dose  Added rationale for the OLE dose 
selection  
5.3. Open -Label 
Extension Period (newly 
added section)  Added new criterion 44, 45, and 46 to 
assess eligibility of participants for 
the OLE period  
6. Study Intervention  Added table describing authorization 
as defined by [CONTACT_695479] -CTR for 
LY3372689 and placebo, and 
updated the definition for study 
intervention  Compliance with EU -CTR  
Packaging and Labeling subsection:  
Added a statement for supply of  
study interventions by [CONTACT_695480] -
label study design  
Approved on [ADDRESS_943585] 2024 GMT
CCI
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
109 
 Section # and Name  [CONTACT_11029]  
6.3. Measures to 
Minimize Bias: 
Randomization and 
Blinding  Added “study periods 2a and 2b” to 
reiterate the duration of double -blind  Added for clarity  
Updated the information in the 
section based on addition of OLE  
period  To reflect the changes in the modified open -
label study design  
6.4. Study Intervention 
Compliance  Indicated that the telephone visits are 
applicable only for the double -blind 
study periods  Added for clarity  
6.5.1. Standard of Care 
for Alzheimer’s Disease  Revised visit number for double -
blind period from “33” to “29”  Error correction  
Specified that approved prescription 
treatments for AD is permitted but 
not a requirement in this study  Added for clarity  
 New paragraph added for 
permitted standard -of-care 
treatments during the OLE 
period  
 Added a heading to clearly 
segregate the double -blind study 
period and the OLE period 
(newly added paragraph)  To reflect the changes in the modified open -
label study design  
6.6. Dose Modification  Updated the information in the 
section based on OLE  6.7. Intervention after 
the End of the Study  
7.2.1. Discontinuation of 
Inadvertently Enrolled 
Participants  Deleted statement which allows 
inadvertently enrolled participants to 
receive  study intervention  For compliance with sponsor’s internal 
procedure  
 
7.3. Lost to Follow -up Deleted paragraph on site personnel 
or an independent third party 
attempting to collect vital status of 
participants  
Added a note regarding actions that 
will be taken by [CONTACT_695481]  
8.5. Pharmacokinetics  Replaced collection of “serum” with 
“plasma” samples of LY3372689  Error correction  
[IP_ADDRESS]. Exploratory 
Biomarkers  
8.8.1. Blood Sample 
Collection for 
Exploratory Biomarkers  Added l anguage for additional testing 
of plasma P -tau217, NFL, and GFAP 
from the exploratory biomarker 
samples  Specifying biomarkers to be tested  
Added “neuroinflammation”  Clarification  
Approved on [ADDRESS_943586] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
110 
 Section # and Name  [CONTACT_11029]  
[IP_ADDRESS]. Exploratory 
Biomarkers  Deleted “gene expression of the OGA 
gene”  Change in assay availability and 
prioritization of biomarkers for primary  data 
base lock  
9. Statistical 
Considerations  
9.2. Sample Size 
Determination  Changed “bMMRM” to “MMRM”  No longer using bMMRM for sensitivity 
analysis to the primary endpoint nor to other 
analyses that were previously planned to use 
bMMRM  
9.4.1. General 
Considerations  Updated the information in the 
section based on OLE  To reflect the changes in the modified open -
label study design  
 Added a statement for handling of 
missing, unused, and spurious 
data 
 Deleted duplicate statement  For EU -CTR compliance  
9.4.2 Primary 
Endpoint(s)  Updated to be specific regarding 
covariates that will be adjusted in the 
primary analysis and additional 
sensitivity analysis  For clarify  
9.4.3. Secondary 
Endpoint(s)  Updated the analytic models that will 
be used for secondary endpoints  To reflect the latest analysis plan for 
secondary endpoints and for clarity.  
9.4.6. Other Safety 
Analyses(s)  Deleted “Other” from the heading  For clarity  
9.5. Interim Analyses  Added statement cross referencing to 
Section 10.1.6. on timing of 
disseminati on of data summaries  To reinforce awareness of the content in 
Section 10 .1.6. 
10.1.1. Regulatory and 
Ethical Considerations  Added specific statement that the 
clinical trial will be conducted in 
compliance with European 
Regulation (EU) No 536/2014, if 
applicable  For EU -CTR compliance  
Added a bullet point regarding 
reporting of significant issues related 
to participant’s safety, rights, and 
data integrity  
10.1.4. Data Protection  Updated the section with required 
language on data protection  
10.1.6. Dissemination of 
Clinical Study Data  Added a new paragraph under  
“Reports”  
Data subsection:  
 Added “ or genetic data” which 
cannot be provided by [CONTACT_103]  
 Updated the website to submit 
data request  As per Lilly template requirements  
10.1.7. Data Quality 
Assurance  Updated section  
Approved on [ADDRESS_943587] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
111 
 Section # and Name  [CONTACT_11029]  
10.2. Appendix 2: 
Clinical Laboratory 
Tests  Additional biomarker testing has 
been included which comprises of  
NFL, GFAP , and P- tau217  Specifying biomarkers to be tested  
10.3.1. Definition of AE  Updated e vents meeting the AE 
definition  and e vents not meeting the 
AE definition  For EU -CTR compliance  
10.3.3. Definition of 
Product Complaints  Updated definition  As per Lilly template requirements  
10.3.6. Regulatory 
Reporting Requireme nts  Updated section  
 Added a new paragraph  to add 
information for SAE regulatory 
reporting  For EU -CTR compliance  
10.5. Appendix 5: 
Flortaucipir F18 Tau 
PET Imaging   Referenced footnote ‘b’ for 
effective dose (mSv) per scan  
 Deleted footnote ‘b’ from number 
of scans in second year  Error correction  
10.9. Appendix 9: 
Abbreviations  Added terms and definitions 
including abuse, authorized IMP, 
IMP, medication error, misuse, SoA, 
and S[LOCATION_003]R  For EU -CTR compliance  
Revised “bMMRM” to “MMRM”  No longer using bMMRM for sensitivity 
analysis to the primary endpoint nor to other 
analyses that were previously planned to use 
bMMRM  
Added “OLE” to the list  To update list of abbreviations  
10.10. Appendix 10: 
Flortaucipir F18 PET 
Imaging and MRI 
Substudy (newly  added 
section)  Added new section for flortaucipir 
F18 PET imaging and MRI scans   
substudy which will be performed in 
approximately [ADDRESS_943588] additional PET and MRI scans in 
participants enrolled in the open -label 
extension period of Study  MTAE on a 
voluntary basis  
Throughout  Minor formatting and editorial 
changes  Minor, therefore, not detailed  
 
 
Amendment [b]: (02-Sep-2021 )   
This amendment is considered to be nonsubstantial.  
Overall Rationale for the Amendment:  
The main rationale of this amendment is to  make an administrative change regarding reference to 
an unblinded pharmacist.   
 
Approved on [ADDRESS_943589] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
112 
 Section # and Name  [CONTACT_9353] 6.3 Measures to 
Minimize Bias: 
Randomization and 
Blinding  Removed reference to drug 
being made available by 
[CONTACT_695482]. 
Reference to the pharmacy 
manual also removed . Minor correction and 
clarification.  
Language corrected regarding 
blinded and unblinded site 
personnel for  drug dispensing . 
Updated text to use dynamic 
allocation (minimization) 
method of Pocock and Simon 
(1975) in randomization 
scheme to achieve as much 
balance as possible across the 
arms on the stratified factors at 
the study level.  
Section 11 References  Added Pocock and S imon, 
1975.  Additional reference for the 
additions made in Section 
6.3. 
Amendment [a]:   (09-Jun-2021 ) 
Overall Rationale for the Amendment:  
The main rationale of this amendment is to change the primary endpoint from the CDR -SB to 
iADRS to improve efficacy signal detection and to add some flexible language for use of P -tau 
as a screening tool considering the potential limited or delayed availab ility in some countries . In 
addition, the mention of specific biomarker assay in exploratory objectives and endpoints  has 
been removed.  
Section # and Name  [CONTACT_9353] 1.[ADDRESS_943590] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
113 
 Section # and Name  [CONTACT_695485] P -tau use in screening 
and as endpoint measure . To reflect changes in 
objectives . 
Updated tolerance interval for 
visit 801.  Correction.  
Section [ADDRESS_943591] recent data reviews 
suggesting improved 
capability of iADRS in 
detecting treatment effects in 
this population . 
Removed mention of specific 
biomarker assay in exploratory 
objectives and endpoints . To allow for accommodation 
of emergent technology . 
Section 4.1.1 Lead -In and 
Screening period (V601 and 
V1) Updated wording to clarify that 
sites can continue with 
flortaucipir F18 PET scanning 
without meeting the P -tau 
screening criterion if the P -tau 
testing is not available at site .  Added protocol flexibility to 
allow for not performing P -
tau as a prescreen prior to tau 
PET in cases where it may 
not be available. All 
participants will be required 
to meet P-tau PET criteria 
for enrollment . 
Section 4.[ADDRESS_943592] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
114 
 Section # and Name  [CONTACT_9353] 6.1 Study 
Intervention(s) 
Administered  Corrected  visit number . Error correction . 
Section 6.3 Measures to 
Minimize Bias: 
Randomization and 
Blinding  Updated text related to 
stratification of participant 
randomization . To allow for potential 
stratification needs for 
emerging approved disease -
modifying therapi[INVESTIGATOR_014] . 
Section 6.[ADDRESS_943593] recent data 
reviews suggesting improved 
capability of iADRS in 
detecting treatment effects in 
this population . 
Minor edits to the model  
description for the primary 
analysis. Added brief 
description in the statistical 
model for the sensitivity 
analysis . Clarification . 
Section 10.2 Appendix 2: 
Clinical Laboratory Tests Removed plasma NfL, plasma 
P-tau, and OGA gene 
expression sample assays . To allow for accommodation 
of emergent technology . 
Approved on [ADDRESS_943594] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
115 
 Section # and Name  [CONTACT_9353] 10.[ADDRESS_943595] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
116 
 11. References   
Berg L, Miller JP, Baty J,  et al. Mild senile dementia of the Alzheimer type. 4. Evaluation of 
intervention. Ann Neurol . 1992;31(3):242 -249. doi: 10.1002/ana.410310303.  
Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective 
multiple test procedures. Stat Med . 2009;28(4):586 -604. doi: 10.1002/sim.3495.   
Bretz F, Posch M, Glimm E,  et al. Graphical approaches for multiple comparison procedures 
using weighted Bonferroni, Simes, or parametric tests. Biom J . 2011;53(6):894 -913. doi: 
10.1002/bimj.201000239.   
Brier M R, Gordon B, Friedrichsen K,  et al. Tau and Aβ imaging, CSF measures, and cognition 
in Alzheimer's disease. Sci Transl Med . 2016;8(338):338ra66. doi: 
10.1126/scitranslmed.aaf2362.  
Cedarbaum JM, Jaros M, Hernandez C,  et al. Rationale for use of the clinical  dementia rating 
sum of boxes as a primary outcome measure for Alzheimer's disease clinical trials. Alzheimers 
Dement.  2013;9([ADDRESS_943596]):S45 -S55. doi: 10.1016/j.jalz.2011.11.002.   
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron . 
1976;16(1):31 -41. doi: 10.1159/000180580.   
Coley N, Andrieu S, Jaros M,  et al. Suitability of the clinical dementia rating -sum of boxes as a 
single primary endpoint for Alzheimer's disease trials. Alzheimers Dement . 2011;7(6):602 -
610.e2.  doi: 10.1016/j.jalz.2011.01.005.  
[CUIMC] Columbia University Irving Medical Center. Columbia -Suicide Severity Rating Scale 
(C-SSRS). The Columbia Lighthouse Project web site. 2016. cssrs.columbia.edu  Accessed  18 
December 2020 . 
[FDA] Food and Drug Administration. early Alzheimer’s disease: developi[INVESTIGATOR_695431]. Guidance for industry . Food and Drug Administration web site. 2018.  
https://www.fda.gov/media/110903/download. Accessed 18 December 2020.  
Fleisher A,  Pontecorvo M,  Devous  M, et al. Positron emission tomog raphy imaging with 
[18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes . 
JAMA Neurol.  2020;77(7):829 -839. doi: 10.1001/jamaneurol.2020.0528.  
Folstein MF, Folstein SE, McHugh PR. “Mini -mental state”. A practical method for grading the 
cognitive state of patients for the clinician. J Psychiatr Res . 1975;12(3):189 -198. doi: 
10.1016/0022 -3956(75)[ZIP_CODE] -6.  
Galasko D, Bennett D, Sano M,  et al. An inventory to assess activities of daily living for clinical 
trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis 
Assoc Disord . 1997;11(Suppl 2):S33 -S39. 
Galasko D, Kershaw PR, Schneider L, et al. Galantamine maintains ability to perform activities 
of daily livi ng in patients with Alzheimer's disease. J Am Geriatr Soc . 2004;52(7):1070 -1076. 
doi: 10.1111/j.1532 -5415.2004.[ZIP_CODE].x.  
Graham DL, Gray AJ, Joyce JA,  et al. Increased O -GlcNAcylation reduces pathological tau 
without affecting its normal phosphorylation in a mouse model of tauopathy. 
Neuropharmacology . 2014;79:307 -313. doi: 10.1016/j.neuropharm.2013.11.025.   
Approved on [ADDRESS_943597] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
117 
 Hastings NB, Wang X, Song L,  et al. Inhibition of O -GlcNAcase leads to elevation of O -
GlcNAc tau and reduction of tauopathy and cerebrospi[INVESTIGATOR_695432]4510 mice. Mol 
Neurodegener.  2017;12(1):39.  doi: 10.1186/s13024 -017-0181 -0.  
Hyman BT, Phelps CH, Beach TG,  et al. National Institute on Aging – Alzhei mer’s Association 
guidelines for the  neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement . 
2012;8(1):1 -13. doi: 10.1016/j.jalz.2011.10.007.  
Hughes CP, Berg L, Danziger WL,  et al. A new clinical scale for the staging of dementia. Br J 
Psychiatry . 1982;140:566 -572. doi: 10.1192/bjp.140.6.566.   
Jack C, Bennett  D, Blennow  K, et al.  NIA-AA Research Framework: Toward a biological 
definition of Alzheimer's disease . Alzheimers Dement . 2018;14(4): 535 -562. doi: 
10.1016/j.jalz.2018.02.018.  
Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P -tau181 in Alzheimer’s disease: 
relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal 
progression to Alzheimer’s dementia. Nat Med . 2020;26(3):379 -386. doi: 10.1038/s41591 -
020-0755 -1. 
Janelidze S, Berron D, Smith R, et al. Associations of Plasma Phospho -Tau217 Levels With Tau 
Positron Emission Tomography in Early Alzheimer Disease . JAMA Neurol . 2020 . 
Nov9:e204201 . doi: 10.1001/jamaneurol.2020.4201.   
Kahle -Wrobleski K, Andrews JS, Belger M,  et al. Clinical and economic characteristics of 
milestones along the continuum of Alzheimer’s disease: transforming functional scores into 
levels of dependence. J Prev Alzheimers Dis. 2015;2(2):115 -120. doi: 10.[ZIP_CODE]/jpad.2015.53.   
Kahle -Wrobleski K, Andrews JS, Belger M,  et al. Dependence levels as interim clinical 
milestones along the continuum of Alzheimer’s disease: 18 -month results from the GERAS 
Observational Study. J Prev Al zheimers Dis . 2017;4(2): 7280.  doi: 10.[ZIP_CODE]/jpad.2017.2.   
Mattsson -Carlgren N, Janelidze S, Palmqvist S,  et al. Longitudinal plasma p -tau217 is increased 
in early stages of Alzheimer's disease . Brain . 2020;143(11):3234 -3241.  doi: 
10.1093/brain/awaa286.  
McLaughlin T, Feldman H, Fillit H,  et al. Dependence as a unifying construct in defining 
Alzheimer’s disease severity. Alzheimers Dement . 2010;6(6):482 -493. doi: 
10.1016/j.jalz.2009.09.004.  
Mohs RC, Knopman D, Petersen RC,  et al. Development of cognitive instruments for use in 
clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale 
that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc 
Disord . 1997;11(Suppl 2):S13 -S21. 
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology . 
1993;43(11):2412 -2414.  doi: 10.1212/wnl.43.11.[ADDRESS_943598] S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho -tau217 
for Alzheimer disease vs other neurodegenerative disorders. JAMA . 2020:324( 8):772 -781. doi: 
10.1001/jama.2020.[ZIP_CODE] . 
Pocock SJ, Simon  R. Sequential treatment assignment with balancing for prognostic factors in 
the controlled clinical trial. Biometrics . 1975 :31(8) :103-115. 
Approved on [ADDRESS_943599] 2024 GMT
CONFIDENTIAL  Protocol I9X-MC-MTAE( e) 
118 
 Pontecorvo M,  Devous M,  Kennedy I,    et al. A multicentre longitudinal study of flortaucipir 
(18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia . Brain , 
2019; 142(6):1723 -1735 . doi: 10.1093/brain/awz090 . 
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry . 
1984;141(11):1356 -1364.  doi: 10.1176/ajp.141.11.1356.  
Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron . 1991;6(4):487 -498. doi: 
10.1016/0896 -6273(91)[ADDRESS_943600]. Mach Learn . 
2016;102(3):393 -441. doi: 10.1007/s10994 -015-5529 -5.  
Spackman DE, Kadiyala S, Neumann PJ,  et al. The validity of dependence as a health outcome 
measure in Alzheimer’s disease. Am J Alzheimers Dis Other Demen . 2013;28(3):245 -252. doi: 
10.1177/1533317513481092.   
Thijssen EH, La Joie R, Wolf A, et al . Advancing Research and Treatment for Frontotemporal 
Lobar Degeneration (ARTFL) investigators. Diagnostic value of plasma phosphorylated 
tau181in Alzheimer’s disease and frontotemporal lobar degeneration. Nature Med . 
2020;26(3):387 -397. https://doi.org/10.1038/s41591 -020-0762 -2. 
Wechsler D.  Wechsler Adult Intelligence Scale —Fourth Edition . Bloomington, MN: PsychCorp, 
an imprint of Pearson Clinical Assessment; 2008.  
Wessels AM, Siemers ER, Yu P,  et al. A combined measure of cognition and function for 
clinical trials: the integrated Alzheimer’s Disease Rating Scale (iADRS). J Prev Alzheimers 
Dis. 2015;2(4):227 -241. doi: 10.[ZIP_CODE]/jpad.2015.82.  
Williams MM, Storandt M, Roe CM, Morris JC. Progression of Alzh eimer's disease as measured 
by [CONTACT_695483]. Alzheimers Dement.  
2013;9([ADDRESS_943601]):S39 -S44. doi: 10.1016/j.jalz.2012.01.005.   
[WMA] World Medical Association. Declaration of Helsinki – ethical principles for medical 
research in volving human subjects. https://www.wma.net/policies -post/wma -declaration -of-
helsinki -ethical -principles -for-medical -research -involving -human -subjects/. October 2013. 
Accessed [ADDRESS_943602] 2017.  
Yuzwa SA, Cheung AH, Okon M,  et al. O-GlcNAc modification of tau  directly inhibits its 
aggregation without perturbing the conformational properties of tau monomers. J Mol Biol.  
2014;426(8):1736 -1752. doi: 10.1016/j.jmb.2014.01.004.  
Approved on [ADDRESS_943603] 2024 GMT
Signature [CONTACT_11032]-CLIN-007992 v4.0
Signature [CONTACT_11032]-CLIN-007992 v4.0Approval
22-Aug-2024 12:47:38 GMT[PHONE_006]
Approval
22-Aug-2024 13:06:56 GMT[PHONE_006]
Approved on [ADDRESS_943604] 2024 GMT
[COMPANY_003]
[COMPANY_003]
Signature [CONTACT_11032]-CLIN-164746 v1.0
Signature [CONTACT_11032]-CLIN-164746 v1.0Approval
06:31 GMT[PHONE_006]
Approved on [ADDRESS_943605] 2024 GMT
[COMPANY_003]